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A B S T R A C T
Background
Recovery strategies are oftenusedwith the intentionof preventing orminimisingmuscle soreness after exercise.Whole-body cryotherapy,
which involves a single or repeated exposure(s) to extremely cold dry air (below -100 °C) in a specialised chamber or cabin for two to
four minutes per exposure, is currently being advocated as an effective intervention to reduce muscle soreness after exercise.
Objectives
To assess the effects (benefits and harms) of whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle
soreness after exercise in adults.
Search methods
We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register, the Cochrane Central Register of Controlled
Trials, MEDLINE, EMBASE, CINAHL, the British Nursing Index and the Physiotherapy Evidence Database. We also searched the
reference lists of articles, trial registers and conference proceedings, handsearched journals and contacted experts.The searches were run
in August 2015.
Selection criteria
We aimed to include randomised and quasi-randomised trials that compared the use of whole-body cryotherapy (WBC) versus a passive
or control intervention (rest, no treatment or placebo treatment) or active interventions including cold or contrast water immersion,
active recovery and infrared therapy for preventing or treating muscle soreness after exercise in adults. We also aimed to include
randomised trials that compared different durations or dosages of WBC. Our prespecified primary outcomes were muscle soreness,
subjective recovery (e.g. tiredness, well-being) and adverse effects.
1Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
Two review authors independently screened search results, selected studies, assessed risk of bias and extracted and cross-checked data.
Where appropriate, we pooled results of comparable trials. The random-effects model was used for pooling where there was substantial
heterogeneity. We assessed the quality of the evidence using GRADE.
Main results
Four laboratory-based randomised controlled trials were included. These reported results for 64 physically active predominantly young
adults (mean age 23 years). All but four participants were male. Two trials were parallel group trials (44 participants) and two were
cross-over trials (20 participants). The trials were heterogeneous, including the type, temperature, duration and frequency of WBC,
and the type of preceding exercise. None of the trials reported active surveillance of predefined adverse events. All four trials had design
features that carried a high risk of bias, potentially limiting the reliability of their findings. The evidence for all outcomes was classified
as ’very low’ quality based on the GRADE criteria.
Two comparisons were tested: WBC versus control (rest or no WBC), tested in four studies; and WBC versus far-infrared therapy, also
tested in one study. No studies compared WBC with other active interventions, such as cold water immersion, or different types and
applications of WBC.
All four trials compared WBC with rest or no WBC. There was very low quality evidence for lower self-reported muscle soreness (pain
at rest) scores after WBC at 1 hour (standardised mean difference (SMD) -0.77, 95% confidence interval (CI) -1.42 to -0.12; 20
participants, 2 cross-over trials); 24 hours (SMD -0.57, 95% CI -1.48 to 0.33) and 48 hours (SMD -0.58, 95% CI -1.37 to 0.21), both
with 38 participants, 2 cross-over studies, 1 parallel group study; and 72 hours (SMD -0.65, 95% CI -2.54 to 1.24; 29 participants,
1 cross-over study, 1 parallel group study). Of note is that the 95% CIs also included either no between-group differences or a benefit
in favour of the control group. One small cross-over trial (9 participants) found no difference in tiredness but better well-being after
WBC at 24 hours post exercise. There was no report of adverse events.
One small cross-over trial involving nine well-trained runners provided very low quality evidence of lower levels of muscle soreness
after WBC, when compared with infrared therapy, at 1 hour follow-up, but not at 24 or 48 hours. The same trial found no difference
in well-being but less tiredness after WBC at 24 hours post exercise. There was no report of adverse events.
Authors’ conclusions
There is insufficient evidence to determine whether whole-body cryotherapy (WBC) reduces self-reported muscle soreness, or improves
subjective recovery, after exercise compared with passive rest or no WBC in physically active young adult males. There is no evidence
on the use of this intervention in females or elite athletes. The lack of evidence on adverse events is important given that the exposure to
extreme temperature presents a potential hazard. Further high-quality, well-reported research in this area is required and must provide
detailed reporting of adverse events.
P L A I N L A N G U A G E S U M M A R Y
Whole-body cryotherapy for preventing and treating muscle soreness after exercise
Background and aim of the review
Delayed onset muscle soreness describes the muscular pain, tenderness and stiffness experienced after high-intensity or unaccustomed
exercise. Various therapies are in use to prevent or reduce muscle soreness after exercise and to enhance recovery. One more recent
therapy that is growing in use is whole-body cryotherapy (WBC). This involves single or repeated exposure(s) to extremely cold dry air
(below -100°C) in a specialised chamber or cabin for two to four minutes per exposure. This review aimed to find out whether WBC
reduced muscle soreness, improved recovery and was safe for those people for whom it can be used.
Results of the search
We searched medical databases up to August 2015 for studies that compared WBC with a control intervention such as passive rest or
no treatment; or with another active intervention such as cold water immersion. We found four small studies. These reported results
for a total of 64 physically active young adults. All but four participants were male. The studies were very varied such as the type,
temperature, duration and frequency of theWBC and the exercises used to induce muscle soreness. There were two comparisons: WBC
compared with a control intervention; and WBC compared with far-infrared therapy.
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Key results
All four studies compared WBC with either passive rest or no treatment. These provided some evidence that WBC may reduce muscle
soreness (pain at rest) at 1, 24, 48 and 72 hours after exercise. However, the evidence also included the possibility that WBC may not
make a difference or may make the pain worse. There was some weak evidence that WBC may improve well-being at 24 hours. There
was no report and probably no monitoring of adverse events in these four studies.
One very small study also compared WBC with far-infrared therapy and reported lower levels of muscle soreness one hour after the
treatment.
Quality of the evidence
All four studies had aspects that could undermine the reliability of their results. We decided that the evidence was of very low quality for
all outcomes. Thus, the findings remain very uncertain and further research may provide evidence that could change our conclusions.
Conclusions
The currently available evidence is insufficient to support the use of WBC for preventing and treating muscle soreness after exercise in
adults. Furthermore, the best prescription of WBC and its safety are not known.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Whole-body cryotherapy (WBC) compared with control (no WBC or passive rest) for preventing and treating muscle soreness after exercise in adults
Patient or population: physically-active adults partaking in exercise designed to produce delayed onset muscle soreness (most trial participants were male)
Settings: laboratory-based
Intervention: whole-body cryotherapy (WBC). The timing, format and modality varied. WBC delivered in either in a specialised cryotherapy chamber (temperature -110°C) or partial-body
cryotherapy (head and neck not included) in a cryo-cabin at temperatures of -110°C or between 140 to -195°C. Exposure: 3 minutes. Timing after exercise ranged from 10 minutes to 24
hours. Repeat exposures, which were every 24 hours in 2 studies, varied from 0 to 5 additional sessions
Comparison: control: no intervention (in chamber but normal temperatures: 15°C and 21°C) or passive rest
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control (rest or no WBC) WBC
Muscle soreness: pain at
rest (VAS)
Follow-up: 1 hour
The mean difference in
muscle soreness in the
WBC groups was
0.77 standard deviations
lower
(1.42 lower to 0.12
lower)
SMD -0.77
(-1.42 to -0.12)
20 participants
(2 studies)
⊕©©©
very low1
Reported in 2 cross-over
studies only
One rule of thumb is that
0.2 represents a small dif-
ference, 0.5 a moderate
difference and 0.8 a large
difference. Based on this
’rule of thumb’, this result
equates to a moderate to
large difference in favour
of WBC
Muscle soreness: pain at
rest (VAS)
Follow-up: 24 hours
The mean difference in
muscle soreness in the
WBC groups was
0.57 standard deviations
lower
(1.48 lower to 0.33
higher)
SMD -0.57
( -1.48 to 0.33)
38 participants
(3 studies)
⊕©©©
very low2
Reported in one paral-
lel group (which found
no difference between the
two groups) and two
cross-over studies which
found in favour of WBC.
Based on the above rule
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of thumb, this results
equates to a moderate
difference in favour of
WBC but also includes a
small to moderate effect
in favour of rest or no
WBC
Muscle soreness: pain at
rest (VAS)
Follow-up: 48 hours
The mean difference in
muscle soreness in the
WBC groups was
0.58 standard deviations
lower
(1.37 lower to 0.21
higher)
SMD -0.58
(-1.37 to 0.21)
38 participants
(3 studies)
⊕©©©
very low2
Reported in one paral-
lel group (which found
no difference between the
two groups) and two
cross-over studies which
found in favour of WBC.
Based on the above rule
of thumb, this results
equates to amoderate dif-
ference in favour of WBC
but also includes a small
effect in favour of rest or
no WBC
Muscle soreness: pain at
rest (VAS)
Follow-up: 72 hours
The mean difference in
muscle soreness in the
WBC groups was
0.65 standard deviations
lower
(2.54 lower to 1.24
higher)
SMD -0.65
(-2.54 to 1.24)
29 participants
(2 studies)
⊕©©©
very low2
Reported in one paral-
lel group (which found
no difference between the
two groups) and one
cross-over study which
found in favour of WBC.
There was substan-
tial heterogeneity be-
tween the two trials (Chi²
= 7.73, df = 1 (P = 0.
005); I² = 87%), which
brings both pooling and
the validity of this result
into question
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Tiredness (0 [no tired-
ness] to 100 [maximum
tiredness])
Follow-ups: 1, 24 and 48
hours
The mean tiredness
recorded in the study con-
trol group at 24 hourswas
49.2
The mean tiredness in the
WBC group was 13.30
lower (32.17 lower to 5.
57 higher)
9 participants
(1 study)
⊕©©©
very low1
Reported in one cross-
over study only.
The results at 1 and 48
hours showed a similar
lack of differences be-
tween the two groups,
with all 95% CIs crossed
the line of no effect
Well-being (0 [worst
well-being] to 100 [opti-
mal well-being])
Follow-ups: 1, 24 and 48
hours
The mean well-being
recorded in the study con-
trol group at 24 hourswas
65.4
The mean well-being in
the WBC group was 21.
7 higher (2.20 to 41.20
higher)
9 participants
(1 study)
⊕©©©
very low1
It is possible that the
difference in well-being
represented a clinically
important difference but
the minimal clinically im-
portant difference is not
known
No differences between
groups were observed at
1 and 48 hour follow-ups;
the 95% CIs crossed the
line of no effect at both
time periods
Adverse events See comment See comment See comment All studies failed to report
active surveillance of pre-
defined adverse events.
We found one report of
skin burn following WBC
in the recent literature.
Studies typically exclude
people with contradic-
tions to cryotherapy, such
as Raynaud’s disease
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; SMD: standardised mean difference
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1The quality of the evidence was downgraded 3 levels for very serious study limitations resulting in a high risk of bias and serious
imprecision (very few participants).
2The quality of the evidence was downgraded 3 levels for very serious study limitations resulting in a high risk of bias, serious imprecision
(very few participants) and serious inconsistency (substantial heterogeneity).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Elite-level athletic participation necessitates recovery from many
physiological stressors, including fatigue to the musculoskeletal,
nervous andmetabolic systems (Nédélec 2013). Athletic participa-
tion may also result in exercise-induced muscle damage (EIMD),
which may lead to delayed-onset muscle soreness (DOMS) and
decrements in subsequent performance (Howatson 2008). Vari-
ous therapeutic modalities of recovery are currently used by ath-
letes in an attempt to offset the negative effects of strenuous exer-
cise (Bieuzen 2013; Bleakley 2012; Costello 2014b; Minett 2015;
Nédélec 2013).
Description of the condition
DOMS is a broad term used to describe themuscular pain, tender-
ness and stiffness experienced after high-intensity, eccentric (when
the muscle is forcibly stretched when active) or unaccustomed ex-
ercise (Cheung 2003; Ebbeling 1989; Howatson 2008; Newham
1987). Clinically associated with EIMD, DOMS is proposed to
result frommechanical disturbances of the muscle membrane that
evoke secondary inflammation, swelling and free radical prolifera-
tion (Connolly 2003). These events typically peak 24 to 96 hours
post exercise (Cheung 2003) and may reduce physical capacity
via alterations in muscle length, maximal force and range of mo-
tion (Prasartwuth 2006; Saxton 1995). Although damage to the
exercised musculature is linked to the biochemical expression of
intracellular enzymes, compensatory neuromuscular recruitment
patterns may contribute both central and peripheral factors to
DOMS aetiology (Byrne 2004).
Symptoms associated with DOMS typically dissipate within five
to seven days post exercise with adequate rest (Cheung 2003).
Nevertheless, various interventions have been advocated to pre-
vent or treat, or both prevent and treat, EIMD and associated
DOMS. Interventions include cool-down, stretching, nutritional
supplements, massage, hydrotherapy, compression, electrotherapy
and non-steroidal anti-inflammatory medications (Bieuzen 2013;
Bleakley 2012; Herbert 2011). Despite their widespread popu-
larity (Nédélec 2013), empirical support for the use of these in-
terventions for DOMS remains tenuous (Bleakley 2012; Herbert
2011).
Description of the intervention
Whole-body cryotherapy (WBC) is increasingly used in sports
medicine as treatment formuscle soreness after exercise. This treat-
ment involves exposing individuals to extremely cold dry air (be-
low -100°C) for two to four minutes. To achieve the subzero tem-
peratures required for WBC, two methods are typically used: liq-
uid nitrogen and refrigerated cold air. During these exposures, in-
dividuals wear minimal clothing, which usually consists of shorts
for males and shorts and a crop top for females. Gloves, a woollen
headband covering the ears, and a nose and mouth mask, in ad-
dition to dry shoes and socks, are commonly worn to reduce the
risk of cold-related injury.
The first WBC chamber was built in Japan in the late 1970s,
but WBC was not introduced to Europe until the 1980s, and
has only been used in the USA and Australia in the past decade
(Miller 2012). The treatment was initially intended for use in a
clinical setting to treat patients with conditions such as multiple
sclerosis (Miller 2012) and rheumatoid arthritis (Hirvonen 2006;
Metzger 2000); however, elite athletes have recently reported using
the treatment to alleviate DOMS after exercise (Bleakley 2014;
Costello 2012a; Fonda 2013; Hausswirth 2011; Pournot 2011).
WBC is commonly employed shortly (within 0 to 24 hours) after
exercise, and the treatment is often repeated on the same day (
Costello 2012a) or over several days (Lubkowska 2012).
In the field of athletic training, a new method of exposing peo-
ple to these extreme temperatures, called partial-body cryotherapy
(PBC), using a portable cryo-cabin, has recently been developed.
This system has an open tank and exposes the body, except the
head and neck, to temperatures below -100°C. Recently, recre-
ational athletes have started to emulate elite athletes in using these
treatments after exercise.
How the intervention might work
Reductions in muscle and skin tissue temperature after WBC ex-
posure (Costello 2012b; Costello 2012c; Costello 2014a) may
stimulate cutaneous receptors and excite the sympathetic adren-
ergic fibres, causing constriction of local arterioles and venules
(Costello 2014d; Savic 2013). Consequently, WBC may be effec-
tive in relieving soreness through reducedmusclemetabolism, skin
microcirculation, receptor sensitivity and nerve conduction veloc-
ity. In addition, both Bleakley 2012 and Cochrane 2004 describe
the potential psychological benefits of using other modalities of
cold exposure (e.g. cold water immersion) to reduce the subjective
feeling of DOMS following exercise.
Although the research examining WBC is typically limited in
terms of quality and statistical power (Costello 2012a; Costello
2012b), some studies have described a reduction in creatine ki-
nase activity after training (Wozniak 2007), increases in parasym-
pathetic activation (Hausswirth 2013; Zalewski 2014) and an
increase in anti-inflammatory cytokines (proteins that serve
to regulate the inflammatory response) (Ferreira-Junior 2014b;
Lubkowska 2010; Lubkowska 2011) after WBC exposure. A re-
duction in the severity of muscle damage after exercise and an
increase in anti-inflammatory cytokines post-treatment may help
to reduce both the initial damage and the secondary inflamma-
tory damage associated with EIMD. However, from a mechanistic
perspective, very little is known about the physiological and bio-
chemical rationale for using WBC in the management of DOMS.
Only a few studies have sought to examine the physiological effects
(Fonda 2014; Hammond 2014; Selfe 2014) of different WBC
8Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
protocols on different population. Selfe 2014 studied the effects
of a 1, 2 and 3 minutes exposure of WBC at -135°C on changes
in the inflammatory cytokine interleukin-six (IL-6), tissue oxy-
genation, skin and core temperature, thermal sensation and com-
fort in professional rugby league players, and concluded that two
minutes was the optimum exposure length that should be applied
as the basis for future studies. Fonda 2014, employing -130 to -
170°C partial-body (head out) cryotherapy, supported these find-
ings and demonstrated that longer durations do not substantially
affect thermal and cardiovascular response, but do increase ther-
mal discomfort in healthy young male adults.
Using the approach described by Anderson 2011, we developed a
logic model to capture the wide range of potential effects of WBC
exposure (Figure 1). This model is divided into two sections: (1)
potential recovery benefits and (2) potential adverse effects. Miss-
ing from this model is any appraisal of the logistical, environmen-
tal and financial costs associated with WBC.
Figure 1. Logic Model describing the potential benefits and adverse effects of whole-body cryotherapy
Why it is important to do this review
This review aimed to examine the effects, both beneficial and
harmful, of WBC used for the purpose of preventing or treat-
ing muscle soreness after exercise. Currently, no guidelines for a
clinically effective or safe WBC protocol are available. Because of
the extreme temperatures employed during WBC, the potential
for short- and long-term adverse effects needs to be elucidated.
A systematic review of the evidence is also important because of
the increasing use of WBC by elite and recreational athletes and
the potential for long-term use throughout a sporting career in an
attempt to alleviate DOMS.
O B J E C T I V E S
To assess the effects (benefits and harms) of whole-body cryother-
apy (extreme cold air exposure) for preventing and treating muscle
soreness after exercise in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We included randomised and quasi-randomised (method of allo-
cating participants to a treatment that is not strictly random, e.g.
by date of birth) controlled clinical trials evaluating whole-body
cryotherapy for prevention and treatment of muscle soreness after
exercise in adults. This included randomised cross-over trials and
trials carried out in laboratory or field settings.
Types of participants
No restrictions were placed on gender or on type or level of exer-
cise. All field- and laboratory-based (including eccentric) exercise
modalities were included. We excluded studies focusing on chil-
dren (< 18 years of age) or on injured participants. As anticipated,
people with vascular problems, such as Raynaud’s disease, who are
contraindicated for cryotherapy, were excluded from trials.
Types of interventions
We included trials inwhich at least one group in the trial comprised
participants treated with whole-body cryotherapy (WBC) before
or after exercise.WBCwas defined as exposure of the body (trunk,
arms and legs) to extremely cold dry air (below -100°C). These
exposures are typically administered as a once-off treatment, or
repeated several times on the same days or over several days.
We aimed to include trials that compared the use of WBC versus
a passive or control intervention (rest, no treatment or placebo
treatment) or active interventions designed to prevent or treat de-
layed-onset muscle soreness (DOMS), including, but not limited
to, cold water immersion (immersion in water colder than 15°C),
warm water immersion (immersion in water warmer than 15°C),
contrast water immersion (alternating hot and cold water immer-
sion), cool-down, stretching, massage and compression garments.
We also aimed to include randomised trials that compared differ-
ent durations or dosages of WBC. We excluded trials in which
the same WBC protocol was used in both arms as a co-interven-
tion. Comparisons with pharmacological interventions were also
excluded.
Types of outcome measures
Trials that did not report any of the primary outcomes were not
included in the review.
Primary outcomes
• Muscle soreness (e.g. pain measured with the use of visual
analogue scales and algometer data)
• Subjective recovery (e.g. tiredness, well-being)
• Immediate or long-term complications or adverse effects
(e.g. frost bite, adverse cardiac or vascular events, musculoskeletal
injury)
Secondary outcomes
• Muscle strength and power (muscle contractile properties)
• Objective test of function and performance (e.g. hop test)
Resource use
We also attempted to collect cost and resource data, including cost
of the intervention and cost of time off work or professional sports
activity.
Timing of outcome assessment
We collected data at the following follow-up times: up to 1 and 24,
48, 72, 96 and more than 96 hours post intervention. These are
typical follow-up times for studies assessing treatment for DOMS.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Bone, Joint andMuscle Trauma Group
Specialised Register (5 August 2015), theCochrane Central Regis-
ter of Controlled Trials (CENTRAL) (The Cochrane Library, 2015
Issue 7), MEDLINE (1946 to July Week 4 2015), MEDLINE
In-Process & Other Non-Indexed Citations (5 August 2015),
EMBASE (1974 to 2015 Week 31), the Cumulative Index to
Nursing and Allied Health (CINAHL) (1982 to 5 August 2015),
the British Nursing Index (BNI) (1985 to 5 August 2015) and
the Physiotherapy Evidence Database (PEDro) (1929 to 7 August
2015).
In MEDLINE, the subject-specific search was combined with
the sensitivity- and precision-maximising version of the Cochrane
Highly Sensitive Search Strategy for identifying randomised trials
(Lefebvre 2011). We present the search strategies for CENTRAL,
MEDLINE, EMBASE, CINAHL and BNI in Appendix 1.
We also searched Current Controlled Trials and the WHO
International Clinical Trials Registry Platform for ongoing and
recently completed trials (7 August 2015) (see Appendix 1).
We applied no language restrictions.
Searching other resources
We searched the reference lists of relevant articles and the table of
contents of the following journals not registered as being hand-
searched by the Cochrane Collaboration:
• (Australian) Journal of Science and Medicine in Sport (1998
to September 2014).
• British Journal of Sports Medicine (1964 to September 2014).
• Clinical Journal of Sport Medicine (1991 to September
2014).
• International Journal of Sports Medicine (2005 to September
2014).
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• Journal of Applied Physiology (1948 to September 2014).
• Journal of Sports Medicine and Physical Fitness (1998 to
September 2014).
• Journal of Sports Sciences (1985 to 1987; 1990 to 1991;
1994; 1996; 2000 to September 2014).
• Medicine and Science in Sports and Exercise (1980 to
September 2014).
• Physical Therapy in Sport (2000 to 2002; 2007 to
September 2014).
We also searched the conference proceedings of the following or-
ganisations:
• American College of Sports Medicine (1986 to September
2014) (in Medicine and Science in Sports and Exercise).
• American Physical Therapy Association (1980 to
September 2014) (in Physical Therapy).
• British Association of Sport and Exercise Medicine
(BASEM) (1964 to September 2014) (in British Journal of Sports
Medicine).
• British Association of Sport and Exercise Sciences (BASES)
(1964 to September 2014) (in Journal of Sports Sciences).
• World Confederation for Physical Therapy (2003, 2007,
2011) (CD-ROM).
Experts and colleagues working in the subject area were also asked
to notify us on the existence of new or ongoing studies, which we
also considered for inclusion.
Data collection and analysis
Selection of studies
Two review authors (JTC, GMM) independently selected trials
for inclusion. First, we screened titles and abstracts of publications
obtained by the search strategy and removed only those that were
obviously outside the scope of the review. We were over-inclusive
at this stage and obtained the full text of any papers that potentially
met the review inclusion criteria. We checked for multiple publi-
cations and reports of the same study. The same two review au-
thors then independently selected trials using a standardised form
to record their choices. We were not blinded during this process
with respect to study authors’ names, journal or date of publica-
tion. When possible, translation of non-English language studies
was undertaken. We contacted primary authors when necessary
to ask for clarification of study characteristics. Disagreement be-
tween the review authors was resolved by consensus or by third
party adjudication (CB, PRAB, IBS).
Data extraction and management
Two review authors (JTC, GMM) used a customised form to in-
dependently extract relevant data on methodology, eligibility cri-
teria, interventions (including detailed characteristics of the ex-
ercise protocols and the WBC protocol employed), comparisons
and outcome measures. Details of the characteristics of trial par-
ticipants such as training status, age, sex and health status were
also recorded. When available, we extracted data on participant
subgroups, including any equity considerations such as ethnicity
and socioeconomic status. Any included study written by one of
the current review authors was reviewed by review authors who
did not participate in the original study. Any disagreement was
resolved by consensus or by third party adjudication (IBS, PRAB).
We contacted primary authors to clarify any omitted data or study
characteristics. For intention-to-treat analysis, data were extracted
according to the original allocation groups, and losses to follow-
up were noted where possible.
Assessment of risk of bias in included studies
Two review authors (JTC, GMM) independently assessed risk of
bias using the tool described (and the criteria outlined) in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). To minimise bias in the interpretation of this scale, two
review authors (JTC,GMM) initially assessed 10 unrelated studies
(not included in the current review); disparities in ’Risk of bias’
judgementswere reviewed anddiscussed before any of the included
studies were evaluated.
Each study was graded for risk of bias in each of the following
domains: sequence generation, allocation concealment, blinding
(participants and intervention providers; outcome assessment),
incomplete outcome data and selective outcome reporting. Two
other sources of bias were also considered on the basis of the fol-
lowing questions: (1) ’Was the exercise protocol clear and consis-
tent between groups?’, and (2) ’Were co-interventions used, and
if so, were they standardised across groups?’. For each study, the
information pertaining to each of the domains was described as
reported in the published study report (or, if appropriate, based
on information from related protocols or published comments,
or after discussion with the relevant authors) and the associated
risk of bias judged by the review authors. Studies were assigned
’high risk’, ’low risk’, or ’unclear risk’ when there was uncertainty
or when information was insufficient to allow review authors to
make a judgement. Disagreements between review authors regard-
ing the ’Risk of bias’ assessment were resolved by consensus.
Measures of treatment effect
For each study, we calculated risk ratios and 95% confidence inter-
vals (CIs) for dichotomous outcomes, and mean differences and
95% CIs for continuous outcomes. For continuous outcomes that
were pooled on different scales, we used standardised mean dif-
ferences (SMDs). Where possible, follow-up scores were used in
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preference to change scores. An exception was made for strength
outcomes, where recovery to baseline is arguably of most interest
to athletes and researchers.
Unit of analysis issues
We extracted data at clinically relevant time points. When avail-
able, data were extracted for, and separate analyses conducted at,
the following time points: up to 1 hour after the exercise and then
at 24-hour intervals (1 to 24 hours, 25 to 48 hours, 49 to 72 hours,
73 to 96 hours and over 96 hours). In studies using a randomised
cross-over design, and where a carry-over effect was not thought
to be a problem, we aimed to undertake paired analysis when suf-
ficient data were available; otherwise, data were analysed as if these
studies used a parallel group design.
Dealing with missing data
In cases where data were missing, we considered why they were
missing. We contacted study authors to request missing data or to
ask for an explanation as to why data were missing. Unless missing
standard deviationswere derived fromCIs, standard errors or exact
P values, we did not assume or impute values for these in order to
present results in the analyses.
Assessment of heterogeneity
Assessment of heterogeneity between comparable trials was eval-
uated visually with the use of forest plots, as well as Chi² tests and
I² statistics. The level of significance for the Chi² test was set at
P = 0.1 (Deeks 2011): a P value for Chi² < 0.1 was considered
to indicate statistically significant heterogeneity between studies.
Values of I² were interpreted as follows: 0% to 40% might not be
important; 30% to 60% may represent moderate heterogeneity;
50% to 90% may represent substantial heterogeneity; and 75%
to 100% may represent considerable heterogeneity.
Assessment of reporting biases
We planned to use funnel plots to assess for publication bias;
however, there were insufficient studies. Should sufficient trials
become available in future, we plan to use funnel plots to assess
for publication bias based on the effect estimates (horizontal scale)
against standard error (on a reversed scale, vertical) using Review
Manager software, with continuous data represented as SMDs,
and dichotomous data represented as risk ratios on a logarithmic
scale.
Data synthesis
Results of comparable groups of trials were pooled using either
fixed-effect or random-effects models. The choice of the model
to report was guided by careful consideration of the extent of
heterogeneity and whether it could be explained, in addition to
other factors, such as the number and size of included studies.
Ninety-five per cent CIs were used throughout.We considered not
pooling data when considerable heterogeneity (I² > 75%) could
not be explained by the diversity of methodological or clinical
features observed among trials. When it was inappropriate to pool
data, we presented trial data in the analyses or tables for illustrative
purposes and reported them in the text.
Subgroup analysis and investigation of heterogeneity
We intended to perform the following subgroup analyses:
• Gender (male versus female)
• Exposure dose (single versus repeated exposures; short
versus long exposure durations)
• Exercise type (normal sporting activities and laboratory-
induced delayed-onset muscle soreness (DOMS))
• Training status (elite versus recreational)
We chose these subgroup analyses because gender, type of athletic
activity and training status may impact the severity of DOMS
experienced after exercise (Howatson 2008; McGinley 2009). In
particular, DOMS may be augmented in untrained males after
eccentric exercise when compared with trained females perform-
ing concentric exercise. Moreover, reductions in tissue tempera-
ture may be more pronounced after repeated, or longer, WBC ex-
posures (Costello 2012c).
We conducted an exploratory subgroup analysis based on study
design: parallel group versus cross-over. As well as issues relating to
potential carry-over effects and suboptimal analysis of cross-over
trials, they are likely to be at increased risk of serious bias where
there is lack of blinding and subjective assessment of outcome.
We investigatedwhether the results of subgroupswere significantly
different by inspecting the overlap of CIs and by performing the
test for determining subgroup differences that is available in Re-
view Manager (RevMan 2014).
Sensitivity analysis
If some of the included trials were at high risk of bias for one or
more domains, we intended to perform sensitivity analysis to de-
termine whether inclusion of such trials significantly influenced
the effect size. We planned to consider trials at high risk of bias in
sensitivity analysis if allocation concealment was unclear or at high
risk of bias, or if attrition was greater than 20%. We performed
sensitivity analysis to explore the effects of using fixed-effect or
random-effects analyses for outcomes with statistical heterogene-
ity.
’Summary of findings’ table
We prepared a ’Summary of findings’ table for the main compar-
ison (WBC versus rest, no or a placebo intervention) using the
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GRADE profiler (Schünemann 2011). We summarised the qual-
ity of evidence by applying the principles of the GRADE frame-
work and following the recommendations and worksheets of the
Cochrane Effective Practice and Organisation of Care Group for
creating ’Summary of findings’ tables (EPOC 2011). We assessed
the quality of the evidence according to four levels (high, mod-
erate, low and very low). We presented the evidence for primary
outcomes only. We selected muscle soreness assessed for pain at
rest at 1, 24, 48 and 72 hours; well-being and tiredness at 24 hours
and adverse events as the 7 outcomes for presenting in a ’Summary
of findings’ table.
R E S U L T S
Description of studies
Results of the search
We screened a total of 1696 records from the following databases:
Cochrane Bone, Joint andMuscle Trauma Group Specialised Reg-
ister (2 records); Cochrane Central Register of Controlled Trials
(388), MEDLINE (332), EMBASE (463), CINAHL (286), BNI
(5), PEDro (87), the WHO International Clinical Trials Registry
Platform (63) and Current Controlled Trials (70). We also found
52 potentially-eligible studies from ongoing searches and through
contacting experts and colleagues working in the subject area.
The search identified a total of 29 articles for potential inclusion,
for which full reports were obtained where possible. Upon fur-
ther analysis, 4 trials (6 articles) were included (Costello 2012;
Ferreira-Junior 2014; Fonda 2013;Hausswirth 2011) and17 stud-
ies (19 articles) were excluded. Four studies are awaiting classifica-
tion pending publication (DRKS00006038; NCT02341612) or
receipt of further information (Krüger 2015; Ziemann 2014).
A flow diagram summarising the study selection process is shown
in Figure 2.
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Figure 2. Study flow diagram
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Included studies
The four included studies, which were published between 2010
and 2014, were laboratory studies conducted in single centres
in France (Hausswirth 2011), Ireland (Costello 2012), Slovenia
(Fonda 2013) and Brazil (Ferreira-Junior 2014). All were pub-
lished in English and in peer-reviewed journals. Three were iden-
tified via database searches and one was identified from searching
conference proceedings (Ferreira-Junior 2014). A full pre-publi-
cation report was obtained from the authors of this trial. All four
studies were randomised controlled trials. Two employed a parallel
group design (Costello 2012; Ferreira-Junior 2014) and two used
a cross-over design (Fonda 2013; Hausswirth 2011). The time
between intervention arms in the cross-over trials was 3 weeks in
Hausswirth 2011 and 10 weeks in Fonda 2013.
Further details of individual trials can be found in the
Characteristics of included studies.
Participants
In total, there were data for 64 trial participants of which only 4
(6.3%)were female; all 4were recruited in 1 trial of 18 participants
(Costello 2012). The mean age of participants in individual trials
was 21 years in Costello 2012, 20 years in Ferreira-Junior 2014,
27 years in Fonda 2013 and 32 years in Hausswirth 2011. The
largest trial included 26 participants (Ferreira-Junior 2014).
Participants were described as physically active (Costello 2012;
Ferreira-Junior 2014; Fonda 2013) or well-trained runners (
Hausswirth 2011).
Details of exercise
The type, duration and intensity of exercise performed varied
across studies. In three studies, the exercise was designed to pro-
duce delayed onset muscle soreness (DOMS) under laboratory-
controlled conditions (Costello 2012; Ferreira-Junior 2014; Fonda
2013). The exercise comprised multiple repetitions (100 repeti-
tions) of resistance to lengthening (eccentric exercise) in Costello
2012; drop jumps (100 jumps) in Ferreira-Junior 2014; and a
combination of drop jumps (50 jumps), bilateral leg curls (50 rep-
etitions) and eccentric leg curls (10 repetitions) in Fonda 2013.
The methodology employed by Costello 2012 targeted a single
muscle group (quadriceps). Athough there was a focus on the
hamstring and quadriceps muscles respectively, Fonda 2013 and
Ferreira-Junior 2014 targeted a number of related muscle groups
using a jumpingprotocol.Hausswirth 2011 employed a 48minute
simulated trail run (incorporating five 3-minute downhill blocks
at a -15% gradient) on a treadmill.
Details of whole-body cryotherapy
All studies employed some type of whole-body cryotherapy
(WBC) after exercise.
Two studies used WBC and exposed participants to a controlled
temperature of -110°C in a specialised cryotherapy chamber (
Costello 2012; Hausswirth 2011). Two studies used partial-body
cryotherapy in a cryo-cabin at temperatures of -110°C (Ferreira-
Junior 2014) and between -140 to -195°C (Fonda 2013). It was
noted by Fonda 2013 that the temperature was measured on the
inner wall of the cabin and not next to the skin. It is likely that
the temperature around the skin surface was lower (Fonda 2013).
Although similar, there are some differences between partial- and
whole-body cryotherapy including:
1. the head is not exposed during partial-body cryotherapy,
2. partial-body cryotherapy uses liquid nitrogen and WBC
uses refrigerated cold air,
3. participants typically walk slowly around a small chamber
during WBC and stand during partial-body cryotherapy, and
4. the temperature is uniformly distributed in the WBC
chamber and not in the cabin (i.e. it is cooler at the bottom of
the cabin compared with the top).
All four studies exposed participants to the cryotherapy for three
minutes. However, before entering the -110°C chamber, Costello
2012 included an additional 20 seconds standing in a -60°C
chamber and Hausswirth 2011 stated that participants traversed
through two separate chambers (at -10°C and -60°C respectively).
Fonda 2013 also stated that the participantswere instructed to turn
around continuously in the cabin during exposure. The timing of
initiating cryotherapy after exercise was not consistent across the
studies. Ferreira-Junior 2014 andHausswirth 2011 initiatedWBC
approximately 10 to 15 minutes after exercise, while Fonda 2013
and Costello 2012 waited until 1 and 24 hours respectively after
exercise. Three studies undertook additional WBC interventions
after completing the exercise session: Costello 2012 (26 hours);
Hausswirth 2011 (at 24, 48, 72 and 96 hours); and Fonda 2013
(at 24, 48, 72, 96 and 120 hours).
Details of comparisons
All four included trials comparedWBCversus control (noWBCor
passive rest). One three-group trial also comparedWBCversus far-
infrared therapy (Hausswirth 2011). This study therefore appears
in both comparisons.
We found no trials evaluating WBC versus other interventions:
cold water immersion (immersion in water colder than 15°C),
warm water immersion (immersion in water warmer than 15°C),
contrast water immersion (alternating hot and cold water immer-
sion), cool-down, stretching, massage or compression garments.
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Nor were there trials evaluating the effectiveness of different du-
rations or dosages of WBC.
Whole-body cryotherapy versus control (no intervention,
passive rest or sham treatment)
The participants in the control groups of Costello 2012 and
Ferreira-Junior 2014 followed the same procedures as the inter-
vention groups but the chamber or cryo-cabin temperature was
set to a temperature of 15°C and 21°C respectively. The control
group comprised ’passive rest’ in Fonda 2013 and seated rest for
30 minutes in a temperate room in Hausswirth 2011.
Whole-body cryotherapy versus far-infrared therapy
One study comparedWBCwith far-infrared therapy (Hausswirth
2011). During the far-infrared therapy, participants lay supine on
the table and the whole body, except the head, was exposed to the
treatment for 30 minutes (4 to 14 µm, 45°C). The number of
treatments was the same for both interventions (15 minutes, 24,
48, 72 and 96 hours post exercise).
Details of outcome measurement
Primary outcomes
All four trials reported on muscle soreness, which was assessed us-
ing a visual analogue scale (VAS). Three studies measured muscle
soreness at rest (Costello 2012; Fonda 2013; Hausswirth 2011);
one during a squat (Fonda 2013) and one while performing an iso-
metric knee extension (Ferreira-Junior 2014). Fonda 2013 assessed
the soreness using a 10 cm (0 “no pain” to 10 “severe pain”) VAS
during the resting and the exercise assessment. Both Hausswirth
2011 (0 “no pain” to 100 “maximum possible” on a web interface)
and Ferreira-Junior 2014 (0 mm “no soreness” to 100mm “severe
soreness”) used a 100-point visual analogue scale. Costello 2012
employed a 10-point (1 “normal, no pain” to 10 “very, very sore”)
VAS to assess muscle soreness across eight different sites in the
lower limb, with the results combined together.
Hausswirth 2011 also measured ’tiredness’ and ’well-being’ using
the same web interface 100-point VAS.
The included studies did not monitor adverse events or complica-
tions relating to the interventions. One study measured tympanic
temperature changes associated with WBC and reported that the
lowest mean temperature (36.6 ± 0.4°C) was observed eight min-
utes after WBC (Costello 2012).
Secondary outcomes
A range of secondary outcomeswas reported. Strengthwas assessed
by all four studies. Three studies used an isokinetic dynamometer
to assess either maximal voluntary torque production knee flexion
(Fonda 2013) or maximal voluntary isometric knee extensor force
(Ferreira-Junior 2014; Hausswirth 2011). Costello 2012 assessed
maximal voluntary isometric knee extensor force on a modified
Tornvall chair.
Two studies reported on power: Costello 2012 assessed peak power
output (% of baseline) during repeated-sprint cycling on a cycle
ergometer and Fonda 2013 examined height (m), max force (N/
kg), max power (W/kg), work (J), and push off duration (s) during
a squat and a counter movement jump on a force plate.
None of the included studies included objective tests of function
or performance (e.g. hop test).
Missing data
In order to calculate effect sizes, raw data from four included stud-
ies were requested from study authors (Costello 2012; Ferreira-
Junior 2014; Fonda 2013;Hausswirth 2011). All were successfully
contacted, with each providing the requested information.
Follow-up
All trials undertook multiple follow-up observations for each
outcome. These included immediately after exercise (Costello
2012; Ferreira-Junior 2014; Hausswirth 2011), 1 hour (Fonda
2013;Hausswirth 2011), 24 hours (Costello 2012; Ferreira-Junior
2014; Fonda 2013; Hausswirth 2011), 48 hours (Costello 2012;
Ferreira-Junior 2014; Fonda 2013; Hausswirth 2011), 72 hours
(Costello 2012; Ferreira-Junior 2014; Fonda 2013; Hausswirth
2011), 96 hours (Costello 2012; Ferreira-Junior 2014; Fonda
2013; Hausswirth 2011) and 120 hours (Fonda 2013) hours post
exercise.
This equated to follow-up observations at 10 to 15minutes (Fonda
2013; Costello 2012), 30 to 45 minutes (Hausswirth 2011) and
24 hours (Ferreira-Junior 2014) after the cryotherapy treatment.
Excluded studies
After appraisal of the full study reports, we excluded 17 studies.
Ten studies were excluded because they did not include a primary
outcome measure of the review (rating of perceived exertion and
rating of thermal discomfort/sensation were not considered to be
measures of subjective recovery) and six studies because they did
not use a relevant WBC intervention. Banfi 2008 was a cohort
study only. Reasons for exclusion for individual studies can be
found in the Characteristics of excluded studies.
Studies awaiting classification
Details of the four studies in this category are shown in the
Characteristics of studies awaiting classification.We have been un-
able to locate a full report of DRKS00006038, which recruited
24 female football players, or of NCT02341612, which recruited
65 male college students. Additional information is being sought
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from the authors of Krüger 2015 and Ziemann 2014; these re-
cruited 11 and 18 physically-active young men respectively.
Risk of bias in included studies
All corresponding authors of the included trials responded to our
requests for any unclear or missing methodological details. Our
requests for information were open-ended to avoid any bias re-
sulting from leading questions. Unless an author specifically stated
that he or she did not understand our question, we avoided mak-
ing multiple requests for information. ’Risk of bias’ judgements
were made by two independent authors, based on information
from trial reports and author correspondence; the results are sum-
marised in Figure 3 and Figure 4. Full details of our ’Risk of bias’
assessments for individual trials are given in the Characteristics of
included studies.
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 4. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Randomisation procedure was described in all four studies. Two
studies used a random numbers generator (Costello 2012; Fonda
2013); Ferreira-Junior 2014 used a random numbers table and
Hausswirth 2011 used a hat draw (confirmed following personal
communication).
Allocation concealment was not adequately described in any of
the included studies. However, in two studies, there was no clear
indication that the investigators would be unable to predict the
prospective group (Fonda 2013; Hausswirth 2011), or in the case
of cross-over trials, the order of treatments to which participants
would be allocated. However, the allocations of the final treatment
in the cross-over studies were predictable following knowledge of
the first treatment. After personal communication, both Costello
2012 and Ferreira-Junior 2014 confirmed that an open random
allocation schedule was employed. Thus both these trials were
rated at high risk of bias for this item.
Blinding
Given the type of intervention, it is impractical to blind partici-
pants or personnel and thus all four trials were inevitably at high
risk of performance bias. We assessed detection bias separately for
objective (e.g. strength) and self-reported outcome measures (e.g.
DOMS). The risk of detection bias was classified as high for self-
reported outcome measures. As it is unclear if the lack of assessor
blinding would influence the objective measures (e.g. strength),
the risk of bias for the objective measures was classified as unclear.
Incomplete outcome data
In general, the losses to follow-up and missing data were poorly
described in the published reports of the included studies. After
correspondence, the authors of two trials confirmed no losses to
follow-up or violation from the study protocol (Costello 2012;
Fonda 2013), whereas the authors of the two other studies con-
firmed there were missing data (Ferreira-Junior 2014; Hausswirth
2011). Two (of 11) participants were dismissed because of incom-
plete outcomes in Hausswirth 2011. Ferreira-Junior 2014 stated
that there were missing data from one individual at two follow-
up points. In personal correspondence, Ferreira-Junior 2014 in-
dicated that these participants were included in the analysis and
that the statistical software, SigmaPlot 11.0, calculated the miss-
ing data and automatically decreased the degree of freedom ac-
cordingly. The risk of attrition bias for both Hausswirth 2011 and
Ferreira-Junior 2014 was classified as unclear.
Selective reporting
None of the studies made any reference to a published protocol or
trial registration. Therefore, bias from selective reporting of results
was difficult to ascertain fully. Hausswirth 2011 did not report on
measured outcomes (biomarkers of inflammation) within the trial
report; however, these data were available from a secondary publi-
cation (Pournot 2011) based on communication with the authors.
Additionally, Hausswirth 2011 only reported data up to 48 hours
post exercise but upon contact, the authors provided unpublished
data on muscle strength for follow-up at 72 and 96 hours follow-
ing exercise. We thus rated this study at high risk of reporting bias.
All studies described outcomes and follow-up times with corre-
sponding results presented by intervention group. In all four stud-
ies, additional raw data were provided by corresponding authors
in order to calculate percentage change from baseline scores and
effect sizes. There was an absence of reporting of adverse events.
Other potential sources of bias
All studies provided in-depth descriptions of the exercise proto-
cols based on exercise type, duration, and intensity. Three stud-
ies stated that participants were asked to refrain from using the
following specified co-interventions for the duration of the study;
medications/supplements (Ferreira-Junior 2014; Fonda 2013;
Hausswirth 2011), electrostimulation (Hausswirth 2011), cold
water immersion (Hausswirth 2011), and stretching (Hausswirth
2011). Diet was controlled over the course of two trials (Fonda
2013;Hausswirth 2011) and exercise using a heart rate monitor in
another (Hausswirth 2011). Ferreira-Junior 2014 also stated that
participants were not allowed to perform any vigorous physical
activity or unaccustomed exercise during the experiment. Costello
2012 did not provide any details on co-interventions in the pub-
lished trial but the authors confirmed that participants were in-
structed to refrain from exercise and using co-interventions over
the course of the experiment. All four studies were rated as low
risk of other bias.
Effects of interventions
See: Summary of findings for themain comparison Summary of
findings: whole-body cryotherapy (WBC) compared with control
(no WBC or passive rest)
The four included studies were divided into two different groups
based on comparison of the primary outcome. Within each com-
parison, results are presented in subcategories based on follow-up
time (1, 24, 48, 72, 96 and 120 hours).
Whole-body cryotherapy (WBC) versus control (no
intervention/rest)
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Four studiesmade this comparison (Costello 2012; Ferreira-Junior
2014; Fonda 2013; Hausswirth 2011).
Primary outcomes
Pain at rest (muscle soreness: VAS, various scales or scores;
highest values = worst pain)
Three studies presented data on muscle soreness at rest based on
various visual analogue scores. Results are presented at six follow-
up times (seeAnalysis 1.1). The pooled results using the fixed-effect
model showed significantly lower levels of soreness in the WBC
group at 1 hour (SMD -0.77, 95% CI -1.42 to -0.12; 2 trials); 24
hours (SMD -0.57, 95% CI -1.12 to - 0.03; 3 trials) and 48 hours
(SMD -0.58, 95% CI -1.12 to -0.04; 3 trials). However, there was
significant heterogeneity in the analyses at 24 and 72 hours and
when applying the random-effects model, the significant findings
in favour ofWBCwere not upheld: 24 hours (SMD-0.57, 95%CI
-1.48 to 0.33); 48 hours (SMD -0.58, 95% CI -1.37 to 0.21); see
Analysis 1.2, Figure 5). The results for remaining follow-up times
also showed no significant differences between groups: 72 hours
(SMD -0.65, 95% CI -2.54 to 1.24; 2 trials); 96 hours (SMD -
0.33, 95% CI -0.95 to 0.30; 2 trials) and 120 hours (SMD -0.32,
95 CI 1.16 to 0.52; 1 trial).
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Figure 5. Forest plot of comparison: Whole-body cryotherapy (WBC) versus passive (no WBC
intervention/rest), outcome: 1.2 Pain - random effects analysis (muscle soreness at rest: VAS).
In the 24, 48, 72 and 96 hours analyses, the cross-over trials have
been combined with Costello 2012, a parallel group trial. Of note,
is that Costello 2012 found no difference between the two groups,
whereas the two cross-over trials found in favour of WBC. An
exploratory subgroup analysis by study design at 24 hours follow-
up illustrates this observation, with a highly statistically significant
test for subgroup differences (Chi² = 4.98, df = 1 (P = 0.03), I² =
79.9%; see Analysis 1.3).
Pain on movement (muscle soreness: VAS, different scales;
highest values = worst pain)
Two studies presented data on muscle soreness during subsequent
exercise based on various visual analogue scores (Ferreira-Junior
2014; Fonda 2013). Pooled SMD results are presented for six
follow-up times (see Analysis 1.4). Though the pooled results for
follow-ups at 1, 24, 48, 72 and 96 hours were in favour of WBC,
the 95%CIs clipped the line of no effect except at 24 hours (SMD
-0.66, 95% CI -1.25 to -0.07; 2 trials). Moreover, the results were
moderately to substantially heterogenous for this follow-up. The
parallel group trial (Ferreira-Junior 2014) showed no difference
between the two groups at all five follow-up times, whereas the
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cross-over trial (Fonda 2013) found significant differences at the
first four follow-up times but not at 96 hours or 120 hours.
Subjective recovery
Tiredness (VAS; highest values = worst tiredness)
Hausswirth 2011, the only study to report subjective recovery,
found no differences between groups in levels of tiredness at 1, 24
and 48 hour follow-ups (see Analysis 1.5).
Well-being (VAS; highest values = best well-being)
Hausswirth 2011 reported that well-being was increased at 24
hours (MD 21.70, 95% CI 2.20 to 41.20) following WBC but
found no differences between groups at 1 and 48 hour follow-ups
(see Analysis 1.6).
Immediate or long-term complications or adverse effects
None of the included studies recorded or reported adverse events
or complications relating to the interventions. Moreover, no study
examined the effects of the chronic use of WBC. It was unclear
whether any study actively monitored specific adverse effects as
part of its outcomes.
Secondary outcomes
Strength (% of baseline; highest values = increased strength)
Maximal strength, which was reported in all four studies, was
assessed over a range of time points post intervention. In order to
complete a meta-analysis on strength as a percentage of baseline,
raw data were sought from all four studies. Despite not being
included in the report of the original study, Hausswirth 2011
provided additional raw data for follow-ups at 72 and 96 hour
post intervention and these data are subsequently included in the
analysis of this review.
Although there was some variation in the measurement device
and contraction type, all four studies tested lower limb strength.
Pooled results over six follow-ups are displayed in Analysis 1.7. At
all follow-up times the best estimates favoured the WBC group
but themean differences were very small and the 95%CI included
the line of no effect at 1 hour (MD 1.76%, 95% CI -4.50 to
8.01%; 3 trials) and at 48 hours (MD 2.69%, 95% CI -2.21 to
7.60%; 4 trials) post exercise. The pooled results showed modest
strength increases in the WBC group at 24 hours (MD 5.16%,
95% CI 0.66 to 9.65%; 3 trials), 72 hours (MD 6.92%, 95%
CI 2.32 to 11.52%; 4 trials) and 96 hours (MD 6.73%, 95% CI
1.87 to 10.87%; 4 trials). Only Fonda 2013 reported results at
120 hours; also finding a significant difference in favour of WBC
(MD 12.60%, 95% CI 0.48 to 24.72%).
The results of statistical tests for heterogeneity for the pooled data
together with the visual inspection of the CIs showed little impor-
tant heterogeneity in the results. An exploratory subgroup analysis
by study design was conducted for the 72 hour follow-up as this
had the greatest heterogeneity (Chi² = 4.30, df = 3 (P = 0.23); I² =
30%). This found no statistically significant differences between
the pooled results of cross-over trials and parallel group trials (test
for subgroup differences: Chi² = 0.01, df = 1 (P = 0.91); I² = 0%;
see Analysis 1.8).
Objective tests of function and performance
Power (jumping performance: final outcome data in
centimetres)
Fonda 2013 found no significant difference between interventions
in squat and counter movement jump (CMJ) height at 1, 24, 48,
72, 96 and 120 hour follow-ups (see Analysis 1.9).
Power (peak power output: % of baseline)
Costello 2012 found no significant difference between interven-
tions in a 5x6 maximal cycle repeated-sprint test at 48, 72 and 96
hour follow-ups (see Analysis 1.10).
No other secondary outcomes were reported in these studies.
Subgroup and sensitivity analyses
Aside from exploratory subgroup analysis based on study design,
there were insufficient data to carry out our planned subgroup
analyses (see Subgroup analysis and investigation of heterogeneity).
Notably, only one study included a sample of female participants
(Costello 2012), and there was significant heterogeneity in the
dosage of WBC and the type of exercise performed in the studies.
Additionally, we performed very limited sensitivity analysis; this
being limited to the inspection of the results of using fixed-effect
versus random-effects models for pooling.
Whole-body cryotherapy versus far-infrared therapy
One cross-over trial involving nine participants compared WBC
with far-infrared therapy after a 48 minute simulated trial run
(Hausswirth 2011).
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Primary outcomes
Pain at rest (muscle soreness: VAS: 100 = worst pain)
Although lower levels of muscle soreness were reported after the
WBC intervention at 1 hour follow-up (MD -26.60 units, 95%
CI -46.25 to -6.95; 100-point VAS, 0 ‘no pain’ to 100 ‘maximum
pain’), no differences between the interventions were observed at
24 and 48 hours (see Analysis 2.1).
Subjective recovery (tiredness: VAS; 100 = worst tiredness)
Participants reported lower levels of tiredness followingWBC at 1
and 24 hour follow-ups (see Analysis 2.2). The results at 48 hours
follow-up still favoured WBC but to a lesser extent and the 95%
CI crossed the line of no effect.
Subjective recovery (well-being: VAS; highest values = best
well-being)
No significant differences betweenWBC and far-infrared therapy
interventions were observed in well-being at 1, 24 and 48 hour
follow-ups (see Analysis 2.3).
Immediate or long-term complications or adverse effects
Hausswirth 2011 did not record or report adverse events or com-
plications relating to the interventions.
Secondary outcomes
Strength (% of baseline)
Knee extensors’ isometric strength was slightly lower after the
WBC intervention at 48 hours (MD -4.50%, 95% CI -8.34 to -
0.66; see Analysis 2.4). No other significant differences were ob-
served at the 4 other follow-up points (1, 24, 72, and 96 hours).
Notably, strength was slightly greater (> 100%) than baseline in 6
of the 10 results presented in Analysis 2.4.
Objective tests of function and performance
Hausswirth 2011 did not record or report any other secondary
outcome measures.
D I S C U S S I O N
Summary of main results
This review examined the effectiveness of whole-body cryotherapy
(WBC) for preventing and treating muscle soreness after exercise.
Four small laboratory-based randomised controlled trials, report-
ing on a total of 64 physically-active adults (60 male; 4 female;
mean age 23 years), were included. The trials were clinically and
methodologically heterogeneous with considerable variation such
as in: study design (two were parallel group studies and two were
cross-over studies); the type and application of WBC, including
modality (whole chamber versus cryo-cabin), timing (WBC un-
dertaken immediately after exercise or 24 hours after exercise),
and the temperature and frequency of WBC; and the type of ex-
ercise (simulation trial run/drop jumps versus 100 eccentric con-
tractions).
The included studies made two comparisons: WBC versus con-
trol (rest or no WBC), tested in four studies; and WBC versus
far-infrared therapy, also tested in one study.The results for the
primary outcomes of muscle soreness (pain at rest at 1, 24, 48 and
72 hours), subjective recovery (tiredness at 24 hours; well-being at
24 hours) and adverse events are summarised here. The very poor
quality of the available evidence for both comparisons means that
we are very uncertain about these results.
Whole-body cryotherapy (WBC) versus control
(passive rest or no WBC intervention)
A summary of the evidence available for the primary outcomes for
this comparison is presented in Summary of findings for the main
comparison. Pooled standardised mean difference (SMD) results
for muscle soreness (pain at rest) favoured WBC after delayed-on-
set muscle soreness (DOMS)-inducing exercise at all four follow-
ups: 1 hour (20 participants, 2 cross-over studies); 24 and 48 hours
(38 participants, 2 cross-over studies, 1 parallel group study); 72
hours (29 participants, 1 cross-over study, 1 parallel group study).
However, the 95% confidence intervals (CIs) also included either
no between-group differences or a benefit in favour of the control
group. The trials were heterogeneous, including in terms of the
’control group’ where that of the two cross-over studies was pas-
sive rest and that of the parallel group study was standing in the
chamber with the temperature set at 15°C. There was statistical
heterogeneity, also shown by the statistically significant results of
the subgroup analysis by study design, where the data from the
cross-over studies were in favour of WBC but those from the par-
allel group study showed no difference between the two groups.
One small cross-over trial found no difference in tiredness but
better well-being after WBC at 24 hours post exercise. There was
no report and probably no monitoring of adverse events.
WBC versus far-infrared therapy
One small cross-over trial involving 9 well-trained runners pro-
vided very low quality evidence of lower levels of muscle soreness
after WBC at 1 hour follow-up, but not at 24 hours or 48 hours.
The same trial found no difference in well-being but less tiredness
after WBC at 24 hours post exercise. There was no report and
probably no monitoring of adverse events.
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Overall completeness and applicability of
evidence
We included four laboratory-based studies with a total of 64 par-
ticipants; but substantially fewer participants were available for
pooling in several primary and secondary outcomes. The major-
ity of participants were young (mean ages between 20.2 and 31.8
years); we suspect that this probably reflects the current WBC
user population. However, only four (6.25%) were female. This
finding tallies with our findings of low participation by females in
research relating to other recovery interventions (Costello 2014c).
It is possible that the results may not be applicable to females.
For example, a recent study demonstrated that skin temperature
following WBC depends upon anthropometric variables and sex,
with females and individuals with a higher adiposity cooling more
(Hammond 2014). It has also been demonstrated that the sever-
ity of muscle damage, and subsequent levels of inflammation
and muscle soreness, is related to the gender of the participants
(Costello 2014c; Enns 2010) as well as to the exercise performed
(Paulsen 2012).
Only two comparisons were tested by the included studies. No-
tably, these studies did not allow a comprehensive review of the
relative effectiveness of different methods of WBC in comparison
with other interventions (e.g. cold water immersion) in treating
DOMS post exercise or in elite athletes.
Therewas also no evidence ondifferent types and timings ofWBC.
Of particular note on timing is that three studies (Ferreira-Junior
2014; Fonda 2013; Hausswirth 2011) both attempted to ‘prevent’
DOMS by treating participants immediately after WBC, while
Costello 2012 attempted to ‘treat’ soreness by utilisingWBCat 24-
hour post exercise when inflammation and DOMS are suggested
to peak.
The clinical relevance of any differences in DOMS may be de-
pendent on several factors such as the time of the outcome, the
capacity for natural recovery after exercise, and the time and costs
associated with treatment (Bennett 2005; Bleakley 2012; Herbert
2011). Bleakley 2012 has suggested that a 13% to 22% difference
in muscle soreness would be important for athletes, particularly
those in an elite sporting environment. In the current review, a re-
duction inmuscle soreness of between ~7% to ~20%was observed
in three studies (Ferreira-Junior 2014; Fonda 2013; Hausswirth
2011), demonstrating a potential positive effect after WBC at 1,
24 and 48 hour follow-ups. This suggests that if WBC is utilised
immediately after exercise, reductions in DOMSmay be clinically
relevant. Due to the limitations of the current evidence base, fur-
ther research is required to support these findings.
Increases in muscle strength that exceed baseline (> 100%) oc-
curred at several follow-up times in Fonda 2013 and Hausswirth
2011. Such increases are unlikely to be observed in a highly-trained
group of athletes and, aside from statistical variation, may reflect
the training status (‘physically active’) of the participants.
Althoughwe could not find any reports of adverse events, given the
absence of active surveillance these findings do not preclude their
existence (Figure 1). Recently, Selfe 2014, examining the optimal
duration ofWBCexposure in 14 professional rugby league players,
reported a case of mild superficial skin burn bilaterally on a mid-
portion of the anterior thigh in one athlete. The investigators
described the skin damage as consisting of “erythema and minor
blistering which appeared in a horizontal strip approximately 2
cm high and 10 cm wide the day following WBC”. The athlete
was a Samoan player with an intolerance to ice packs who did not
disclose his cold intolerance to the study team or personnel. It is
well established that cold injuries are more prevalent in individuals
of African descent compared with their Caucasian counterparts
(Golden 2014; Imray 2009). This greater sensitivity to cold may
be explained by a more intense protracted vasoconstriction in the
peripheries during cold exposure (Iampietro 1959; Maley 2014).
However, as the studies included in this review did not undertake
active surveillance for predefined adverse events, the short- and
long-term safety of WBC remains unknown.
As with most recovery interventions, trained or elite athletes are
most likely to use WBC on a regular basis. Although DOMS is
most prevalent in novice athletes, we acknowledge that it may also
occur in elite sport: e.g. at the beginning of the season (when re-
turning to training following a period of reduced activity), after
injury or after the introduction of a new movement or training
method, especially if eccentric in nature. WBC has also been ad-
vocated in a clinical and rehabilitative setting as a way to reduce
pain and inflammation (symptoms also associated with DOMS);
however, our findings are less applicable to these settings.
Quality of the evidence
On the basis of GRADE (Grades of Recommendation, Assess-
ment, Development and Evaluation) criteria, the quality of evi-
dence for the primary outcomes, muscle soreness and subjective
recovery, was classified as ‘very low’ across all follow-up times. The
reasons for downgrading the evidence were study limitations (es-
pecially lack of blinding) resulting in a high risk of bias, impreci-
sion reflecting the very small sample sizes, and, where pooling was
possible, inconsistency reflecting substantial heterogeneity. The
reasons for downgrading for individual outcomes for the WBC
versus control comparison are detailed in Summary of findings for
the main comparison. Although there were no complications or
side effects reported within any of the individual studies, it was
unclear whether any study actively monitored specific adverse ef-
fects. For similar reasons, the quality of evidence was also judged
as ’very low’ for all other outcomes including strength. Reflect-
ing serious study limitations and serious imprecision, the evidence
for the second comparison, WBC versus far-infrared therapy, was
classified as ’very low’.
There is a high degree of inter-individual differences in the level
and duration of muscle soreness experienced after exercise. Cross-
over designs are therefore popular in this area of research, with
two such studies included in this review (Fonda 2013; Hausswirth
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2011). The two other studies in the review employed a paral-
lel group design (Costello 2012; Ferreira-Junior 2014). Bleakley
2012 and Bleakley 2014 have previously described how cross-over
designs can risk certain carry-over effects between exercise and
treatment periods, which are not present in parallel group designs.
Insufficient recovery from the first exercise bout is a likely carry-
over effect, particularly when studies induce DOMS on an un-
trainedpopulation. Secondly, during subsequent exercise bouts pa-
tients may experience reduced levels of muscle soreness or muscle
damage. This repeated bout effect has been demonstrated to last
for several months in humans (Howatson 2008; McHugh 1999;
McHugh 2003; Nosaka 2005; Nosaka 1995). The two cross-over
studies in this review used a time frame of 3 weeks (Hausswirth
2011) and 10 weeks (Fonda 2013) between treatment periods.
However, it is still possible that the timeframe used by Hausswirth
2011 may be appropriate as the trialists used well-trained indi-
viduals completing familiar running exercises, who were likely to
recover faster.
Potential biases in the review process
In this review, we undertook an extensive search of electronic
databases and grey literature sources. Although we think this is
likely to have identified all relevant published studies, it is possible
that some unpublished studies have beenmissed andwe cannot, in
addition, rule out publication bias. To the best of our knowledge,
the first randomised controlled trial conducted in this area was
accepted for publication in December 2010 (Costello 2012). This
appears to be the first study which sought to examine the effec-
tiveness of WBC as a post exercise recovery intervention to reduce
DOMS. We anticipate that the effectiveness of this intervention
on treating or preventing DOMS post exercise is likely to be the
focus of more research in the near future. We have not, however,
identified any ongoing trials.
One potential source of bias is the post-hoc exclusion of trials not
reporting our primary outcomes (see Types of outcome measures).
However, none of the excluded studies were aimed at the treatment
of DOMS.
As none of the included studies had a registered protocol, bias
from selective reporting of results was difficult to fully ascertain.
However, we made a concerted attempt to retrieve missing sum-
mary and raw data, and were able to contact all of the authors.
Two of the included studies used a randomised cross-over de-
sign. However, we were unable to perform any paired analysis and
data were analysed as if these studies used a parallel group design.
Cross-over studies were also combined with parallel group trials in
the same meta-analysis. Although this approach gives rise to bias
through unit of analysis error, this is expected to be conservative as
cross-over studies analysed in this way tend to be under-weighted
(Deeks 2011). Other Cochrane reviews (Bleakley 2012; Herbert
2011) have used a similar approach when assessing interventions
to ameliorate DOMS. Inspection of the findings for muscle sore-
ness of the two cross-over studies, and our exploratory subgroup
analysis based on study design, showed that cross-over designs had
a more positive effect on the primary outcome (muscle soreness at
rest), compared with the parallel group trial reporting these data
(Costello 2012). The reasons for this are not clear and the sample
size is inadequate to speculate. Of note, however, is that a similar
finding applied in Bleakley 2012. We suggest that parallel studies
represent the better methodological design for future research in
this area.
Agreements and disagreements with other
studies or reviews
A recent review, conducted by several authors of the current re-
view, that includes a more general perspective has also noted the
limited evidence base supporting the use of WBC in an athletic or
rehabilitative setting (Bleakley 2014). Bleakley 2014 included 10
controlled trials, of which 3 randomised controlled trials (RCTs)
appear in this review (Costello 2012; Fonda 2013; Hausswirth
2011). It did not include data from the latest published RCT
(Ferreira-Junior 2014) included in the current review. Bleakley
2014 demonstrated that WBC induces tissue-temperature reduc-
tions that are comparable to, or less significant than, traditional
forms of cryotherapy such as coldwater immersion and ice pack ap-
plication. AlthoughWBCwas reported tohave a positive influence
on inflammatory mediators, antioxidant capacity, and autonomic
function during sporting recovery, the findings were based on
weak evidence from controlled studies (Bleakley 2014). Bleakley
2014 concluded that there is some weak evidence that WBC im-
proves the perception of recovery and soreness after exercise but
that this does not translate into enhanced functional recovery or
performance. None of the 10 trials reported adverse events asso-
ciated with WBC; but as found in our review, none of the studies
appeared to undertake active surveillance of predefined adverse
events.
Of the three other Cochrane reviews examining the effectiveness
of cold water immersion, stretching, and hyperbaric oxygen ther-
apy for treating muscle soreness after exercise, only that for cold
water immersion found some evidence of benefit (Bleakley 2012).
Bleakley 2012 found some evidence that cold water immersion re-
duces delayed onset muscle soreness after exercise compared with
passive interventions involving rest or no intervention; however,
there was insufficient evidence to draw conclusions on other out-
comes or for other comparisons in this review. Herbert 2011 con-
cluded that available evidence suggests that muscle stretching does
not produce clinically important reductions in DOMS in healthy
adults. Bennett 2005 also found little evidence to support the use
of hyperbaric oxygen therapy to reduce DOMS after exercise, but
also noted some evidence that this intervention may increase in-
terim pain. The finding of benefit from cold water immersion,
which is a cheaper intervention thanWBC, provides an important
context in which to view the results of our review.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence from randomised controlled trials to
determine whether whole-body cryotherapy (WBC) reduces self-
reported muscle soreness, or improves subjective recovery, after
exercise comparedwith passive rest or noWBC in physically-active
young adult males. There is no evidence on adverse events nor or
on the use of this intervention in females or elite athletes. There is
insufficient evidence to draw any conclusions on the relative effects
of WBC versus far-infrared therapy, and no evidence to inform on
the relative effects of WBC versus other active interventions such
as cold water immersion, or on the best protocol for WBC.
Given the limitations of the evidence, the safety concerns relating
to any or repeated exposure to extreme temperatures, and the self-
limiting nature of most forms of muscle soreness resulting from
exercise, there is currently insufficient evidence to support the use
of WBC after exercise.
Implications for research
Based on the apparent increasing use of whole-body cryotherapy
(WBC) in elite and recreational sport, and the costs associatedwith
the WBC, there is an urgent need for high-quality, well-reported
research in the area. It is recommended that future studies should:
incorporate a randomised controlled parallel group design with
adequate sequence generation and allocation concealment; use ap-
propriate sample sizes with power to detect expected differences;
and undertake active surveillance of predefined adverse events. Fu-
ture studies comparing the effects of WBC with other commonly
used recovery interventions for which there is evidence of effec-
tiveness, such as for cold water immersion, is also warranted. Of
note is the identification of an unpublished trial comparing the
effects of three different formats of cold water immersion (single
exposure at 5°C; single exposure at 15°C and multiple exposures
at 10°C), WBC at 110°C and passive recovery (control group)
on DOMS that has recently been completed, and is likely to be
included in subsequent updates of this review. Trials including fe-
males and elite athletes in this area are warranted. Should WBC
be found to be effective, research on the best protocols for WBC
is needed; this might aim to establish, for instance, whether there
is a specific time frame after exercise when this intervention might
be most effective. Also for consideration is research, in particu-
lar evaluating safety issues, assessing the effects of long-term or
chronic use of WBC.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Costello 2012
Methods Randomised controlled trial (parallel group)
Participants Setting: laboratory, Ireland
n = 18 (2 groups of 9) healthy physically-active university students (14 males), mean age
21.2 (SD 2.1)
Inclusion/exclusion criteria
Participants were excluded if they had a history of lower limb injuries in the past 12
months, ear or vestibular conditions or if they had any contradiction to cryotherapy
including Raynaud’s disease. They were also excluded if they were not between the ages
of 18 and 40, not physically active for an average of 3 days a week or not comfortable
with being blind-folded during testing
Interventions Exercise
100 maximal eccentric contractions (5 reps, 20 sets) of the left knee extensors completed
on an isokinetic dynamometer set at an angular velocity of 1.57 rad/s. There was a
minimum rest period of 1 minute between sets
Intervention
Treatment occurred 24 hours post-exercise and again 2 hours later (26 hours post-
exercise)
1. WBC (n = 9; 2 females, 7 males): participants walked around a -110°C chamber
for 3 minutes after standing in a -60°C pre-cooling chamber for 20 seconds. Male
participants wore shorts only. Female participants wore shorts and a crop top or sports
bra. All participants wore two pairs of gloves, a surgical mask, woollen headband, dry
shoes and socks.
2. Control (n = 9; 2 females, 7 males): participants completed the same procedures
as the intervention group; however, the chamber temperature was set to 15°C.
Outcomes Outcomes included in this review
Primary outcomes
Muscle soreness
Self-palpation at 8 sites corresponding to the proximal and distal regions of the knee
extensor and flexors (10-point visual analogue scale: 1 “normal, no pain” to 10 “very,
very sore”)
Secondary outcomes
Force
Maximal voluntary isometric (MVIC) knee extensor force (modified Tornvall chair, 90°
flexion, % of baseline)
Power
Peak power output (PPO) during repeated-sprint cycling (cycle ergometer,% of baseline)
Outcomes not reported in this trial
Subjective recovery (return to previous activity)
Immediate or long-term implications
Objective test of function or performance
Outcomes included in the trial but excluded from this review
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Costello 2012 (Continued)
Tympanic temperature (°C)
Joint position sense (absolute, relative and variable error, °)
(Follow-up: MVIC 1, 24, 48, 72 and 96 hours post-exercise; soreness 24, 48, 72 and 96
hours post-exercise; PPO 24, 48 and 72 hours post-exercise)
Source of Funding Manuscript states “The authors would like to acknowledge ... Shannon Cryotherapy
Clinic, Ennis, Co. Clare, Ireland, for the use of their cryotherapy chamber.”’(p. 197)
Notes Raw data on muscle soreness, power and force provided by Costello J in March 2014
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “participants were randomly assigned, us-
ing a random number generator” (p. 191)
Allocation concealment (selection bias) High risk An open random allocation schedule was
employed (personal correspondence)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Incomplete blinding. Treatment concealed
until after exercise. Difficult to blind par-
ticipant or personnel to treatment
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No details in manuscript.
Blinding of outcome assessment (detection
bias)
Self reported
High risk Participant was aware of the treatment in-
tervention, thus muscle soreness is likely to
be biased
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nodrop-outs reported (confirmedwith au-
thor).
Selective reporting (reporting bias) Low risk No published protocol available. Out-
comes and follow-ups stated in methods.
Means and standard deviations (SD) pre-
sented by intervention group for all out-
comes, at all follow-ups
Other bias Low risk Exercise protocol clearly described.
“Subjects were also instructed to refrain
from consuming alcohol or caffeine 24 h
before testing commenced.” (p. 191)
Manuscript states “The authors would like
to acknowledge ... Shannon Cryotherapy
Clinic, Ennis, Co. Clare, Ireland, for the
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use of their cryotherapy chamber.” (p. 197)
Ferreira-Junior 2014
Methods Randomised controlled trial (parallel group)
Participants Setting: laboratory, Brazil
n = 26 (2 groups of 13) healthy physically-active male university students, mean age 20.
2 (SD 2.5)
Inclusion/exclusion criteria
Participants were excluded if they had untreated arterial hypertension, cardiovascular
and respiratory diseases, angina, peripheral artery occlusive disease, venous thrombosis,
urinary tract diseases, severe anaemia, allergy to cold, tumour diseases, viral and bacterial
infections, Raynaud’s syndrome, claustrophobia or convulsions
Interventions Exercise
100 drop jumps (20 reps, 5 sets) from a 0.6 m box with 2 minute rest intervals between
sets
Intervention
1. WBC (n = 13 males): treatment occurred ~10 minutes after exercise. Participants
were exposed for 3 minutes to low temperatures (from -110°C) using a cryo-cabin.
Participants wore bathing suits, gloves, socks and shoes.
2. Control (n = 13 males): participants completed the same procedures as the
intervention group; however, the cabin was set to 21°C.
Outcomes Outcomes included in this review
Primary outcomes
Muscle soreness
Knee extensormuscle strength sorenessmeasured during amaximal isometric contraction
of the right extensors (100 mm visual analogue scale: 0 “no soreness” to 100 “severe
soreness”)
Secondary outcomes
Force
Maximal voluntary isometric knee extensor peak torque (dynamometer, 60° flexion, %
of baseline)
Outcomes not reported in this trial
Subjective recovery (return to previous activity)
Immediate or long-term implications
Objective test of function or performance
Outcomes included in the trial but excluded from this review
Muscle thickness
(Follow-up: 1, 24, 48, 72 and 96 hours post exercise)
Source of Funding None. The study was partially funded by CAPES - Brazil.
Notes Raw data on muscle soreness and force provided by Ferreira-Junior J in March 2014
Risk of bias
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Ferreira-Junior 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “participants were randomly assigned, us-
ing a random number table” (manuscript
via personal correspondence)
Allocation concealment (selection bias) High risk “we didn’t conceal the allocation of the in-
dividuals” (personal correspondence)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No details in manuscript. Difficult to blind
participant or personnel to treatment
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No details in manuscript.
Blinding of outcome assessment (detection
bias)
Self reported
High risk Participant was aware of the treatment in-
tervention, thus muscle soreness is likely to
be biased
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “onemissing data in the control group (one
subject at 48 h) and another in the WBC
group (one subject at 96 h). The statistical
software that we used, SigmaPlot 11.0, cal-
culates the missing data and automatically
decreases the degree of freedomaccordingly
the number of missing data” (personal cor-
respondence)
Selective reporting (reporting bias) Low risk No published protocol available. Out-
comes and follow-ups stated in methods.
Means and SD presented by intervention
group for all outcomes, at all follow-ups
Other bias Low risk Exercise protocol clearly described.
Manuscript states “Volunteers were not al-
lowed to perform any vigorous physical
activities or unaccustomed exercise during
the experiment period. They were also in-
structed not to take medications or supple-
ments during the study.” (p. 3)
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Fonda 2013
Methods Randomised cross-over (10 weeks between interventions)
Participants Setting: laboratory, Slovenia
n = 11 healthy young male adults, mean age 26.9 years (SD 3.8)
Inclusion/exclusion criteria
Inclusion criteria were that the participants were familiar with plyometric exercise, but
they did not perform this type of exercise for at least 3 months prior to the study, were
not injured or receiving any medications in the last 9 months, were omnivore, and were
within normal baseline levels for biochemical markers
Interventions Exercise
15 min warm-up. Five sets of 10 drop jumps from a 0.6 m high box. Followed by 5 x
10 bilateral leg curls (75% of concentric 1RM in a prone position. Finally, participants
completed 10 eccentric leg curls. The series of drop jump and leg curl exercises were
separated by 1 minute breaks
Intervention
Treatment occurred ~1 hour after exercise and at the same time of the day for the next
6 days
1. WBC (n = 11): Participants were exposed for 3 minutes to low temperatures
(from -140 to -195 °C) using a cryo-cabin. The person’s feet were protected with warm
shoes, while hands and head were not exposed. The participants were instructed to
turn around continuously in the cabin.
2. Control (n = 11): No treatment. [Treatment involved ’passive rest’: (personal
correspondence)]
Outcomes Outcomes included in this review
Primary outcomes
Pain
Perceived pain at rest and during a squat (10 cm visual analogue scale, 0 “no pain” to 10
“severe pain”)
Secondary outcomes
Force
Maximal voluntary torque production knee flexion (dynamometer, 60° flexion, % of
baseline)
Peak average torque in a 1 second time interval.
Rate of torque development in the first 200 ms.
Power
Squat jump (force plate, height {m}, max force {N/kg}, max power {W/kg}, work {J},
push off duration {s})
Counter movement jump (force plate, height {m}, max force {N/kg}, max power {W/
kg}, work {J}, push off duration {s}, counter movement duration {s})
Outcomes not reported in this trial
Subjective recovery (return to previous activity)
Immediate or long-term implications
Outcomes included in the trial but excluded from this review
Aspartate aminotransferase (IU/L)
Creatine kinase (IU/L)
Lactate dehydrogenase (IU/L)
(Follow-up: 1, 24, 48, 72, 96 and 120 hours post exercise)
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Fonda 2013 (Continued)
Source of Funding Manuscript states ”The authors would like to thank Bostjan Benedetti (Krios Ltd, Slove-
nia) and Butan Plin Ltd for providing the cryo-cabin and the liquid nitrogen, respec-
tively.“ (p. 8)
Notes Raw data on muscle soreness, torque, rate of torque development and jump height
provided by Fonda B in March 2014
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Subjects were randomly assigned into two
groups and exposed to a crossover study
design. Randomization has been carried
out with a custom-written algorithm in
LabVIEW (National Instruments, Austin,
Texas, USA).“ (p. 2)
Allocation concealment (selection bias) Unclear risk No details in manuscript.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No details in manuscript. Difficult to blind
participant or personnel to treatment
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No details in manuscript.
Blinding of outcome assessment (detection
bias)
Self reported
High risk Participant was aware of the treatment in-
tervention, thus muscle soreness is likely to
be biased
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed all trials (per-
sonal correspondence)
Selective reporting (reporting bias) Low risk No published protocol available. Out-
comes and follow-ups stated in methods.
Means and SD presented by intervention
group for all outcomes, at all follow-ups
Other bias Low risk Exercise protocol clearly described.
Manuscript states “Between the sessions,
the subjects were not allowed to participate
in any kind of vigorous physical activity.”
(p. 3)
Manuscript states ”theywere not permitted
to drink alcohol or take any medications or
dietary supplements.“ (p. 2)
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Fonda 2013 (Continued)
Manuscript states “The influence of re-
peated bout effect was evident in pain mea-
sures, squat jump start power, and squat
jump work. However, due to small sample
size, it is difficult to draw conclusions that
in other parameters the repeated bout ef-
fect was not present.” (p. 7)
Manuscript states “The authors would like
to thank Bostjan Benedetti (Krios Ltd,
Slovenia) and Butan Plin Ltd for providing
the cryo-cabin and the liquid nitrogen, re-
spectively.” (p. 8)
Hausswirth 2011
Methods Randomised cross-over (3 weeks between interventions)
Participants Setting: laboratory, France
n = 9 well-trained [male: (personal correspondence)] runners, mean age 31.8 (SD 6.5)
Note: 11 participants were recruited but 2were excluded because of incomplete outcomes
(personal correspondence)
Inclusion/exclusion criteria
Minimal performance of 38minutes in a 10 km running race and completing aminimum
of 4 training sessions per week. Presented no contradictions to WBC or far-infrared
radiation therapy
Interventions Exercise
Simulated trial run lasting 48minutes. The protocol was divided into 5 blocks; 6minutes
flat (0% gradient), 3 minutes uphill (10% gradient) and 3 minutes downhill (-15%
gradient)
Intervention
Treatment occurred following the trial run (within the first hour) and again at 24 and
48 hours [participants were also treated at 72 and 96 hours; personal correspondence]
1. WBC (n = 9): participants walked around a -110°C chamber for 3 minutes after
passing through 2 pre-cooling chambers (-10 and -60°C). Participants wore a bathing
suit, surgical mask, ear-band, triple layer gloves, dry socks and sabots. Following
exposure, participants were seated in a temperate room (24°C) for 10 minutes.
2. Passive (n = 9): Seated rest for 30 minutes.
3. Far-infrared radiation (FIR) (n = 9): 30 minutes exposure to FIR. The whole
body, except for the head, was treated with FIR (4-14 µm, 45°C)
Outcomes Outcomes included in this review
Primary outcomes
Pain
Perceived pain (web interface 100 point visual analogue scale, 0 “no pain” to 100 “max-
imum possible”)
Secondary outcomes
Force
Maximal voluntary isometric knee extensor force (isokinetic ergometer, 70° flexion, %
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Hausswirth 2011 (Continued)
of baseline)
Outcomes not reported in this trial
Subjective recovery (return to previous activity)
Immediate or long term implications
Objective test of function or performance
Outcomes included in the trial but excluded from this review
Plasma creatine kinase (% of baseline)
Perceived tiredness (web interface 100 point visual analogue scale, 0 “no tiredness” to
100 “maximum possible”)
Perceived well-being (web interface 100 point visual analogue scale)
(Follow-up: post, 1, 24 and 48 hours post exercise)
[Follow-up data at 72 and 96 hours for knee extensor force were also provided following
personal correspondence]
Source of Funding The authors had no funding to report.
Notes Raw data on muscle soreness and force provided by Bieuzen F in March 2014
The authors confirmed that 11 participants were recruited but 2 were excluded in the
final analysis due to missing outcomes at various time points (personal correspondence
with Bieuzen F in March 2014)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects were randomly assigned…” (p. 3)
.
[drawn from a hat: (personal correspon-
dence)]
Allocation concealment (selection bias) Unclear risk No details in manuscript.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No details in manuscript. Difficult to blind
participant or personnel to treatment
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No details in manuscript.
Blinding of outcome assessment (detection
bias)
Self reported
High risk Participant was aware of the treatment in-
tervention, thus muscle soreness is likely to
be biased
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “There are missing data. Two subjects were
excluded because they did not complete all
the tests (these two participants did not
complete the strength tests even if they have
completed all of the other tests). But all pre-
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Hausswirth 2011 (Continued)
sented data were complete.” (personal cor-
respondence)
Selective reporting (reporting bias) High risk No published protocol available. Out-
comes and follow-ups stated in methods.
Means and SD presented by intervention
group for all outcomes, at all follow-ups ex-
cept at 72 and 96 hours
Other bias Low risk Exercise protocol clearly described.
Training loads between treatments were
monitored and controlled
Manuscript states “to control the influ-
ence of other recovery modalities, nutri-
tional recommendations were sent to run-
ners during all the experiment and they
were asked to respect identical menus dur-
ing the three days preceding and succeed-
ing the running sessions” (p. 3)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Banfi 2008 This was a cohort study involving 10 male athletes
Brand 2010 No WBC intervention
Chen 1996 Unclear if intervention is WBC (from abstract). Although unable to source full text or to contact the
authors, it is unlikely to be WBC as the intervention lasted for 15 minutes
Ferreira-Junior 2014c No primary outcomes
Gailiera 2013 No primary outcomes
Guilhem 2013 Treatment not WBC (-30°C air pulse cryotherapy)
Hausswirth 2013 No primary outcomes
Lapier 1995 No WBC intervention
Schaal 2013 No outcomes relating to DOMS. This study incorporated active recovery in a swimming pool with WBC
Schaal 2015a No outcomes relating to DOMS
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(Continued)
Selfe 2014 No outcomes relating to DOMS
Smolander 2004 No primary outcomes
Szpotowicz-Czech 2014 No primary outcomes
Utsunomiya 2010 No WBC intervention
Venter 2014 No WBC intervention
Wechsler 2014 No primary outcomes (conference abstract only)
Ziemann 2012 No primary outcomes
Characteristics of studies awaiting assessment [ordered by study ID]
DRKS00006038
Methods Randomised controlled trial. Masking: open (not blinded)
Participants 24 female football players
Inclusion criteria required the participants to be in good overall health, possess health insurance, provide written
consent for participation in the study, and not miss any of the training sessions held during the study’s duration. Age
19 to 26 years
Exclusion criteria included contraindication to being subjected to extremely low temperatures and presence of any
form of injury to the lower limbs
Interventions WBC: 10 cryo-stimulation treatments held everyday for a period of 10 days; 1 minute in an atrium of the cryo-
chamber at the temperature -60°C and then, it was continued for 3 minutes in the main cryogenic chamber at the
temperature -130°C
Control: no treatment
Outcomes Quadriceps muscles strength was tested using the Biodex Multi-Joint Testing and Rehabilitation System 3 PRO.
Static, dynamic and endurance tests were performed.
Examinations of quadriceps peak torque were conducted on the first day (Pre 1) before the experimental group had
their first cryotherapy treatment and on the tenth day (Post 2) after the last cryotherapy treatment was completed. The
isokinetic strength tests were performed by the experimental group both before (A) and after (B) the first cryotherapy
treatment and before (C) and after (D) the tenth cryotherapy treatment. The same measurements at the same time
intervals were performed in the control group
Notes This completed trial, conducted in Poland, was retrospectively registered on 1 April 2014. It is not clear, but seems
unlikely, that muscle soreness was assessed. We have not found a full report of this trial
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Krüger 2015
Methods Randomised controlled trial
Participants 11 healthy, non-smoking, endurance-trained male athletes
Interventions Running ramp test followed by high intensity intermittent running, followed by WBC/control and another ramp
test
WBC: 3 minutes of WBC at -110°C
Control: slow walking for 3 minutes at 22°C
Outcomes Perceived physical fitness
Perceived physical energy
Perceived physical flexibility
Perceived physical health
Perceived sensation of recovery
Readiness to train
[Follow-up: post treatment and post second ramp test]
Notes Currently awaiting more information regarding methodology and outcome measures
NCT02341612
Methods Randomised controlled trial
Participants 65, 18 to 30 year old male college students
Interventions Exercise protocol for exercise-induced muscle damage is unclear
WBC: 3 minutes of WBC at -110°C
Cold water immersion (CWI): 5°C single exposure for 20 minutes
CWI: 15°C single exposure for 20 minutes
CWI: 10°C multiple exposures [immediately, 24, 48 and 72 hours post exercise] for 20 minutes
Control: passive rest
Outcomes Muscle soreness: knee extensors (visual analogue scale)
Power: counter-movement vertical jump
[Follow-up: 0, 24, 48, 72, 96 and 168 post exercise]
Notes This trial, conducted in Brazil, has a registered protocol. The trial registration document indicates that the trial was
completed by January 2015. We have not found a full report of this trial
Ziemann 2014
Methods Randomised controlled trial
Participants 18 healthy and physically-active, college-aged men
Interventions 30-minute step up/down work-out.
WBC: 3 minutes of WBC at -110°C twice a day for 5 days (n = 9)
Control: passive rest (n = 9)
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Ziemann 2014 (Continued)
Outcomes Muscle soreness
Ratings of perceived soreness (DOMS)
[Follow-up: 24 hours post exercise]
Notes Currently awaiting more information regarding methodology
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D A T A A N D A N A L Y S E S
Comparison 1. Whole-body cryotherapy (WBC) versus control (no WBC or passive rest)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain (muscle soreness at rest:
VAS)
3 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 1 hour (pain at rest) 2 40 Std. Mean Difference (IV, Fixed, 95% CI) -0.77 [-1.42, -0.12]
1.2 24 hour (pain at rest) 3 58 Std. Mean Difference (IV, Fixed, 95% CI) -0.57 [-1.12, -0.03]
1.3 48 hour (pain at rest) 3 58 Std. Mean Difference (IV, Fixed, 95% CI) -0.58 [-1.12, -0.04]
1.4 72 hour (pain at rest) 2 40 Std. Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.28, 0.08]
1.5 96 hour (pain at rest) 2 40 Std. Mean Difference (IV, Fixed, 95% CI) -0.33 [-0.95, 0.30]
1.6 120 hour (pain at rest) 1 22 Std. Mean Difference (IV, Fixed, 95% CI) -0.32 [-1.16, 0.52]
2 Pain - random effects analysis
(muscle soreness at rest: VAS)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 1 hour (pain at rest) 2 40 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-1.42, -0.12]
2.2 24 hour (pain at rest) 3 58 Std. Mean Difference (IV, Random, 95% CI) -0.57 [-1.48, 0.33]
2.3 48 hour (pain at rest) 3 58 Std. Mean Difference (IV, Random, 95% CI) -0.58 [-1.37, 0.21]
2.4 72 hour (pain at rest) 2 40 Std. Mean Difference (IV, Random, 95% CI) -0.65 [-2.54, 1.24]
2.5 96 hour (pain at rest) 2 40 Std. Mean Difference (IV, Random, 95% CI) -0.33 [-0.95, 0.30]
2.6 120 hour (pain at rest) 1 22 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-1.16, 0.52]
3 Subgroup analysis. Study design:
Pain at 24 hours (muscle
soreness at rest: VAS)
3 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 cross-over 2 40 Std. Mean Difference (IV, Fixed, 95% CI) -1.02 [-1.69, -0.35]
3.2 parallel group 1 18 Std. Mean Difference (IV, Fixed, 95% CI) 0.29 [-0.64, 1.22]
4 Pain (muscle soreness on
movement: cm)
2 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 1 hour (pain on
movement)
2 48 Std. Mean Difference (IV, Fixed, 95% CI) -0.43 [-1.01, 0.16]
4.2 24 hour (pain on
movement)
2 48 Std. Mean Difference (IV, Fixed, 95% CI) -0.66 [-1.25, -0.07]
4.3 48 hour (pain on
movement)
2 48 Std. Mean Difference (IV, Fixed, 95% CI) -0.57 [-1.16, 0.01]
4.4 72 hour (pain on
movement)
2 48 Std. Mean Difference (IV, Fixed, 95% CI) -0.53 [-1.12, 0.05]
4.5 96 hour (pain on
movement)
2 48 Std. Mean Difference (IV, Fixed, 95% CI) -0.31 [-0.89, 0.26]
4.6 120 hour (pain on
movement)
1 22 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.84, 0.84]
5 Tiredness (0 [no tiredness] to
100 [maximum tiredness])
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 1 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 24 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 48 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Well-being (0 [worst well-being]
to 100 [optimal well-being])
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 1 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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6.2 24 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 48 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Strength (% of baseline) 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 1 hour 3 58 Mean Difference (IV, Fixed, 95% CI) 1.76 [-4.50, 8.01]
7.2 24 hour 3 66 Mean Difference (IV, Fixed, 95% CI) 5.16 [0.66, 9.65]
7.3 48 hour 4 84 Mean Difference (IV, Fixed, 95% CI) 2.69 [-2.21, 7.60]
7.4 72 hour 4 84 Mean Difference (IV, Fixed, 95% CI) 6.92 [2.32, 11.52]
7.5 96 hour 4 84 Mean Difference (IV, Fixed, 95% CI) 6.37 [1.87, 10.87]
7.6 120 hour 1 22 Mean Difference (IV, Fixed, 95% CI) 12.60 [0.48, 24.72]
8 Subgroup analysis. Study design:
Strength at 72 hour (% of
baseline)
4 84 Mean Difference (IV, Fixed, 95% CI) 6.92 [2.32, 11.52]
8.1 cross-over 2 40 Mean Difference (IV, Fixed, 95% CI) 6.70 [0.85, 12.56]
8.2 parallel group 2 44 Mean Difference (IV, Fixed, 95% CI) 7.28 [-0.16, 14.71]
9 Power (jump height: centimetres) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 1 hour (Squat jump) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 1 hour (CMJ) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 24 hour (Squat jump) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.4 24 hour (CMJ) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.5 48 hour (Squat jump) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.6 48 hour (CMJ) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.7 72 hour (Squat jump) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.8 72 hour (CMJ) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.9 96 hour (Squat jump) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.10 96 hour (CMJ) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.11 120 hour (Squat jump) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.12 120 hour (CMJ) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Power (cycle ergometer: % of
baseline)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 48 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 72 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 96 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Whole-body cryotherapy (WBC) versus far infrared therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain (muscle soreness at rest:
VAS)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 1 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 24 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 48 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Tiredness (0 [no tiredness] to
100 [maximum tiredness])
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 1 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 24 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 48 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Well-being (0 [worst well-being]
to 100 [optimal well-being])
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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3.1 1 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 24 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 48 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Strength (% of baseline) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 1 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 24 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 48 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 72 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 96 hour 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest),
Outcome 1 Pain (muscle soreness at rest: VAS).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest)
Outcome: 1 Pain (muscle soreness at rest: VAS)
Study or subgroup WBC Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 hour (pain at rest)
Fonda 2013 11 0.1 (0.3) 11 0.8 (0.9) 52.4 % -1.00 [ -1.90, -0.11 ]
Hausswirth 2011 9 31.7 (23.8) 9 44.3 (23.7) 47.6 % -0.51 [ -1.45, 0.44 ]
Subtotal (95% CI) 20 20 100.0 % -0.77 [ -1.42, -0.12 ]
Heterogeneity: Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
2 24 hour (pain at rest)
Costello 2012 9 22.9 (4.7) 9 21.1 (7) 34.2 % 0.29 [ -0.64, 1.22 ]
Fonda 2013 11 0.5 (0.5) 11 1.7 (1.2) 34.1 % -1.26 [ -2.19, -0.33 ]
Hausswirth 2011 9 33.3 (26.1) 9 53.9 (25.5) 31.7 % -0.76 [ -1.73, 0.21 ]
Subtotal (95% CI) 29 29 100.0 % -0.57 [ -1.12, -0.03 ]
Heterogeneity: Chi2 = 5.50, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 2.06 (P = 0.039)
3 48 hour (pain at rest)
Costello 2012 9 31.7 (14.7) 9 29 (10.4) 34.0 % 0.20 [ -0.72, 1.13 ]
Fonda 2013 11 0.8 (0.7) 11 1.9 (1.2) 35.5 % -1.08 [ -1.98, -0.17 ]
Hausswirth 2011 9 39 (24) 9 58.9 (19) 30.5 % -0.88 [ -1.85, 0.10 ]
Subtotal (95% CI) 29 29 100.0 % -0.58 [ -1.12, -0.04 ]
Heterogeneity: Chi2 = 4.24, df = 2 (P = 0.12); I2 =53%
-2 -1 0 1 2
Favour WBC Favours control
(Continued . . . )
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Study or subgroup WBC Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 2.11 (P = 0.035)
4 72 hour (pain at rest)
Costello 2012 9 22.4 (13) 9 18.9 (8.5) 53.0 % 0.30 [ -0.63, 1.23 ]
Fonda 2013 11 0.2 (0.6) 11 1.3 (0.7) 47.0 % -1.62 [ -2.61, -0.63 ]
Subtotal (95% CI) 20 20 100.0 % -0.60 [ -1.28, 0.08 ]
Heterogeneity: Chi2 = 7.73, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 1.74 (P = 0.082)
5 96 hour (pain at rest)
Costello 2012 9 12.3 (5.3) 9 13 (4.1) 45.8 % -0.14 [ -1.07, 0.78 ]
Fonda 2013 (1) 11 0 (0.4) 11 0.2 (0.4) 54.2 % -0.48 [ -1.33, 0.37 ]
Subtotal (95% CI) 20 20 100.0 % -0.33 [ -0.95, 0.30 ]
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
6 120 hour (pain at rest)
Fonda 2013 (2) 11 0 (0.3) 11 0.1 (0.3) 100.0 % -0.32 [ -1.16, 0.52 ]
Subtotal (95% CI) 11 11 100.0 % -0.32 [ -1.16, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
-2 -1 0 1 2
Favour WBC Favours control
(1) Currently using sd of Passive used in WBC need to do inverse calculations for cross over trials
(2) SD of control was 0. Used the sd of the control group 0.3 to calculate effects size
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Analysis 1.2. Comparison 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest),
Outcome 2 Pain - random effects analysis (muscle soreness at rest: VAS).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest)
Outcome: 2 Pain - random effects analysis (muscle soreness at rest: VAS)
Study or subgroup WBC Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 1 hour (pain at rest)
Fonda 2013 11 0.1 (0.3) 11 0.8 (0.9) 52.4 % -1.00 [ -1.90, -0.11 ]
Hausswirth 2011 9 31.7 (23.8) 9 44.3 (23.7) 47.6 % -0.51 [ -1.45, 0.44 ]
Subtotal (95% CI) 20 20 100.0 % -0.77 [ -1.42, -0.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
2 24 hour (pain at rest)
Costello 2012 9 22.9 (4.7) 9 21.1 (7) 33.6 % 0.29 [ -0.64, 1.22 ]
Fonda 2013 11 0.5 (0.5) 11 1.7 (1.2) 33.6 % -1.26 [ -2.19, -0.33 ]
Hausswirth 2011 9 33.3 (26.1) 9 53.9 (25.5) 32.7 % -0.76 [ -1.73, 0.21 ]
Subtotal (95% CI) 29 29 100.0 % -0.57 [ -1.48, 0.33 ]
Heterogeneity: Tau2 = 0.40; Chi2 = 5.50, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 1.25 (P = 0.21)
3 48 hour (pain at rest)
Costello 2012 9 31.7 (14.7) 9 29 (10.4) 33.7 % 0.20 [ -0.72, 1.13 ]
Fonda 2013 11 0.8 (0.7) 11 1.9 (1.2) 34.4 % -1.08 [ -1.98, -0.17 ]
Hausswirth 2011 9 39 (24) 9 58.9 (19) 32.0 % -0.88 [ -1.85, 0.10 ]
Subtotal (95% CI) 29 29 100.0 % -0.58 [ -1.37, 0.21 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 4.24, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 1.45 (P = 0.15)
4 72 hour (pain at rest)
Costello 2012 9 22.4 (13) 9 18.9 (8.5) 50.4 % 0.30 [ -0.63, 1.23 ]
Fonda 2013 11 0.2 (0.6) 11 1.3 (0.7) 49.6 % -1.62 [ -2.61, -0.63 ]
Subtotal (95% CI) 20 20 100.0 % -0.65 [ -2.54, 1.24 ]
Heterogeneity: Tau2 = 1.62; Chi2 = 7.73, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 0.68 (P = 0.50)
5 96 hour (pain at rest)
Costello 2012 9 12.3 (5.3) 9 13 (4.1) 45.8 % -0.14 [ -1.07, 0.78 ]
Fonda 2013 11 0 (0.4) 11 0.2 (0.4) 54.2 % -0.48 [ -1.33, 0.37 ]
-2 -1 0 1 2
Favours WBC Favours control
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Study or subgroup WBC Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 20 20 100.0 % -0.33 [ -0.95, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
6 120 hour (pain at rest)
Fonda 2013 (1) 11 0 (0.3) 11 0.1 (0.3) 100.0 % -0.32 [ -1.16, 0.52 ]
Subtotal (95% CI) 11 11 100.0 % -0.32 [ -1.16, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
-2 -1 0 1 2
Favours WBC Favours control
(1) SD of control was 0. Used the sd of the control group 0.3 to calculate effects size
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Analysis 1.3. Comparison 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest),
Outcome 3 Subgroup analysis. Study design: Pain at 24 hours (muscle soreness at rest: VAS).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest)
Outcome: 3 Subgroup analysis. Study design: Pain at 24 hours (muscle soreness at rest: VAS)
Study or subgroup WBC Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 cross-over
Fonda 2013 11 0.5 (0.5) 11 1.7 (1.2) 51.8 % -1.26 [ -2.19, -0.33 ]
Hausswirth 2011 9 33.3 (26.1) 9 53.9 (25.5) 48.2 % -0.76 [ -1.73, 0.21 ]
Subtotal (95% CI) 20 20 100.0 % -1.02 [ -1.69, -0.35 ]
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.98 (P = 0.0029)
2 parallel group
Costello 2012 9 22.9 (4.7) 9 21.1 (7) 100.0 % 0.29 [ -0.64, 1.22 ]
Subtotal (95% CI) 9 9 100.0 % 0.29 [ -0.64, 1.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Chi2 = 4.98, df = 1 (P = 0.03), I2 =80%
-2 -1 0 1 2
Favours WBC Favours control
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Analysis 1.4. Comparison 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest),
Outcome 4 Pain (muscle soreness on movement: cm).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest)
Outcome: 4 Pain (muscle soreness on movement: cm)
Study or subgroup WBC Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 hour (pain on movement)
Ferreira-Junior 2014 13 46 (29) 13 46 (28) 57.7 % 0.0 [ -0.77, 0.77 ]
Fonda 2013 11 0.8 (1.1) 11 2.3 (1.7) 42.3 % -1.01 [ -1.91, -0.11 ]
Subtotal (95% CI) 24 24 100.0 % -0.43 [ -1.01, 0.16 ]
Heterogeneity: Chi2 = 2.79, df = 1 (P = 0.09); I2 =64%
Test for overall effect: Z = 1.43 (P = 0.15)
2 24 hour (pain on movement)
Ferreira-Junior 2014 13 41 (23) 13 48 (28) 59.0 % -0.26 [ -1.04, 0.51 ]
Fonda 2013 11 2.6 (1.2) 11 4.4 (1.6) 41.0 % -1.22 [ -2.15, -0.30 ]
Subtotal (95% CI) 24 24 100.0 % -0.66 [ -1.25, -0.07 ]
Heterogeneity: Chi2 = 2.43, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 2.18 (P = 0.030)
3 48 hour (pain on movement)
Ferreira-Junior 2014 13 46 (29) 13 54 (26) 57.1 % -0.28 [ -1.05, 0.49 ]
Fonda 2013 11 2.8 (1.7) 11 4.7 (2.1) 42.9 % -0.96 [ -1.85, -0.06 ]
Subtotal (95% CI) 24 24 100.0 % -0.57 [ -1.16, 0.01 ]
Heterogeneity: Chi2 = 1.26, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 1.92 (P = 0.055)
4 72 hour (pain on movement)
Ferreira-Junior 2014 13 25 (20) 13 29 (24) 57.7 % -0.18 [ -0.95, 0.60 ]
Fonda 2013 11 1.5 (1.3) 11 3.1 (1.7) 42.3 % -1.02 [ -1.92, -0.12 ]
Subtotal (95% CI) 24 24 100.0 % -0.53 [ -1.12, 0.05 ]
Heterogeneity: Chi2 = 1.94, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 1.78 (P = 0.075)
5 96 hour (pain on movement)
Ferreira-Junior 2014 13 16 (14) 13 19 (19) 54.9 % -0.17 [ -0.94, 0.60 ]
Fonda 2013 11 0.4 (0.5) 11 0.8 (1) 45.1 % -0.49 [ -1.34, 0.36 ]
Subtotal (95% CI) 24 24 100.0 % -0.31 [ -0.89, 0.26 ]
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
-2 -1 0 1 2
Favours WBC Favours control
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Study or subgroup WBC Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
6 120 hour (pain on movement)
Fonda 2013 11 0.4 (0.5) 11 0.4 (0.5) 100.0 % 0.0 [ -0.84, 0.84 ]
Subtotal (95% CI) 11 11 100.0 % 0.0 [ -0.84, 0.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
-2 -1 0 1 2
Favours WBC Favours control
Analysis 1.5. Comparison 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest),
Outcome 5 Tiredness (0 [no tiredness] to 100 [maximum tiredness]).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest)
Outcome: 5 Tiredness (0 [no tiredness] to 100 [maximum tiredness])
Study or subgroup WBC Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 hour
Hausswirth 2011 9 44.6 (26.3) 9 52.2 (27) -7.60 [ -32.23, 17.03 ]
2 24 hour
Hausswirth 2011 9 35.9 (19.4) 9 49.2 (21.4) -13.30 [ -32.17, 5.57 ]
3 48 hour
Hausswirth 2011 9 46.6 (24) 9 60.7 (26.7) -14.10 [ -37.55, 9.35 ]
-50 -25 0 25 50
Favours WBC Favours control
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Analysis 1.6. Comparison 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest),
Outcome 6 Well-being (0 [worst well-being] to 100 [optimal well-being]).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest)
Outcome: 6 Well-being (0 [worst well-being] to 100 [optimal well-being])
Study or subgroup WBC Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 hour
Hausswirth 2011 9 74.9 (26.7) 9 69.8 (25.3) 5.10 [ -18.93, 29.13 ]
2 24 hour
Hausswirth 2011 9 87.1 (21.1) 9 65.4 (21.1) 21.70 [ 2.20, 41.20 ]
3 48 hour
Hausswirth 2011 9 81.2 (20.4) 9 68.7 (28.1) 12.50 [ -10.19, 35.19 ]
-100 -50 0 50 100
Favours control Favours WBC
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Analysis 1.7. Comparison 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest),
Outcome 7 Strength (% of baseline).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest)
Outcome: 7 Strength (% of baseline)
Study or subgroup WBC Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 hour
Costello 2012 9 60.2 (18.5) 9 61.1 (10.7) 20.1 % -0.90 [ -14.86, 13.06 ]
Fonda 2013 11 91.7 (12.4) 11 86.5 (12.4) 36.4 % 5.20 [ -5.16, 15.56 ]
Hausswirth 2011 9 92.4 (8.3) 9 92.3 (11.9) 43.5 % 0.10 [ -9.38, 9.58 ]
Subtotal (95% CI) 29 29 100.0 % 1.76 [ -4.50, 8.01 ]
Heterogeneity: Chi2 = 0.68, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
2 24 hour
Ferreira-Junior 2014 13 76.2 (11.9) 13 70.2 (14) 20.3 % 6.00 [ -3.99, 15.99 ]
Fonda 2013 11 96.8 (16.2) 11 83.5 (11.1) 15.0 % 13.30 [ 1.69, 24.91 ]
Hausswirth 2011 9 98.2 (5.2) 9 95.2 (6.8) 64.7 % 3.00 [ -2.59, 8.59 ]
Subtotal (95% CI) 33 33 100.0 % 5.16 [ 0.66, 9.65 ]
Heterogeneity: Chi2 = 2.49, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 2.25 (P = 0.025)
3 48 hour
Costello 2012 9 86.2 (18.5) 9 89.4 (12.1) 11.5 % -3.20 [ -17.64, 11.24 ]
Ferreira-Junior 2014 13 83.3 (14.3) 13 74 (16.1) 17.6 % 9.30 [ -2.41, 21.01 ]
Fonda 2013 11 99 (22.6) 11 86.3 (16.5) 8.8 % 12.70 [ -3.84, 29.24 ]
Hausswirth 2011 9 97.9 (3.9) 9 97.4 (8.7) 62.1 % 0.50 [ -5.73, 6.73 ]
Subtotal (95% CI) 42 42 100.0 % 2.69 [ -2.21, 7.60 ]
Heterogeneity: Chi2 = 3.75, df = 3 (P = 0.29); I2 =20%
Test for overall effect: Z = 1.08 (P = 0.28)
4 72 hour
Costello 2012 9 91.8 (13.7) 9 93.6 (12.9) 14.0 % -1.80 [ -14.09, 10.49 ]
Ferreira-Junior 2014 13 90.4 (10.2) 13 77.9 (13.8) 24.3 % 12.50 [ 3.17, 21.83 ]
Fonda 2013 11 104.2 (16.9) 11 92.3 (10.6) 15.2 % 11.90 [ 0.11, 23.69 ]
Hausswirth 2011 9 104.8 (7.1) 9 99.8 (7.5) 46.5 % 5.00 [ -1.75, 11.75 ]
Subtotal (95% CI) 42 42 100.0 % 6.92 [ 2.32, 11.52 ]
-20 -10 0 10 20
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(Continued . . . )
53Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup WBC Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 4.30, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 2.95 (P = 0.0032)
5 96 hour
Costello 2012 9 101 (14.3) 9 96.4 (10.4) 15.2 % 4.60 [ -6.95, 16.15 ]
Ferreira-Junior 2014 13 97.9 (7.6) 13 85.1 (15.4) 23.2 % 12.80 [ 3.46, 22.14 ]
Fonda 2013 11 102.9 (16.5) 11 92.3 (8.9) 16.5 % 10.60 [ -0.48, 21.68 ]
Hausswirth 2011 9 105 (7.1) 9 102.9 (7.4) 45.1 % 2.10 [ -4.60, 8.80 ]
Subtotal (95% CI) 42 42 100.0 % 6.37 [ 1.87, 10.87 ]
Heterogeneity: Chi2 = 4.03, df = 3 (P = 0.26); I2 =26%
Test for overall effect: Z = 2.77 (P = 0.0055)
6 120 hour
Fonda 2013 11 107.1 (16.7) 11 94.5 (11.9) 100.0 % 12.60 [ 0.48, 24.72 ]
Subtotal (95% CI) 11 11 100.0 % 12.60 [ 0.48, 24.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.042)
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Analysis 1.8. Comparison 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest),
Outcome 8 Subgroup analysis. Study design: Strength at 72 hour (% of baseline).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest)
Outcome: 8 Subgroup analysis. Study design: Strength at 72 hour (% of baseline)
Study or subgroup WBC Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 cross-over
Fonda 2013 11 104.2 (16.9) 11 92.3 (10.6) 15.2 % 11.90 [ 0.11, 23.69 ]
Hausswirth 2011 9 104.8 (7.1) 9 99.8 (7.5) 46.5 % 5.00 [ -1.75, 11.75 ]
Subtotal (95% CI) 20 20 61.7 % 6.70 [ 0.85, 12.56 ]
Heterogeneity: Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 2.24 (P = 0.025)
2 parallel group
Costello 2012 9 91.8 (13.7) 9 93.6 (12.9) 14.0 % -1.80 [ -14.09, 10.49 ]
Ferreira-Junior 2014 13 90.4 (10.2) 13 77.9 (13.8) 24.3 % 12.50 [ 3.17, 21.83 ]
Subtotal (95% CI) 22 22 38.3 % 7.28 [ -0.16, 14.71 ]
Heterogeneity: Chi2 = 3.30, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 1.92 (P = 0.055)
Total (95% CI) 42 42 100.0 % 6.92 [ 2.32, 11.52 ]
Heterogeneity: Chi2 = 4.30, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 2.95 (P = 0.0032)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
-20 -10 0 10 20
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Analysis 1.9. Comparison 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest),
Outcome 9 Power (jump height: centimetres).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest)
Outcome: 9 Power (jump height: centimetres)
Study or subgroup WBC Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 hour (Squat jump)
Fonda 2013 11 25.5 (1.7) 11 25.4 (2.1) 0.10 [ -1.50, 1.70 ]
2 1 hour (CMJ)
Fonda 2013 11 30.3 (2.3) 11 29.8 (3.4) 0.50 [ -1.93, 2.93 ]
3 24 hour (Squat jump)
Fonda 2013 11 23.7 (1.6) 11 24.7 (2.4) -1.00 [ -2.70, 0.70 ]
4 24 hour (CMJ)
Fonda 2013 11 30.2 (2.7) 11 28.9 (3.3) 1.30 [ -1.22, 3.82 ]
5 48 hour (Squat jump)
Fonda 2013 11 25.4 (2) 11 24.7 (2.4) 0.70 [ -1.15, 2.55 ]
6 48 hour (CMJ)
Fonda 2013 11 30.3 (2.2) 11 30 (3.2) 0.30 [ -1.99, 2.59 ]
7 72 hour (Squat jump)
Fonda 2013 11 25.8 (1.3) 11 25.7 (2.6) 0.10 [ -1.62, 1.82 ]
8 72 hour (CMJ)
Fonda 2013 11 30.9 (2.1) 11 31.4 (3.6) -0.50 [ -2.96, 1.96 ]
9 96 hour (Squat jump)
Fonda 2013 11 26.5 (2.3) 11 26 (2.9) 0.50 [ -1.69, 2.69 ]
10 96 hour (CMJ)
Fonda 2013 11 31.3 (3) 11 31.2 (4.6) 0.10 [ -3.15, 3.35 ]
11 120 hour (Squat jump)
Fonda 2013 11 26.5 (2.2) 11 26.5 (2.6) 0.0 [ -2.01, 2.01 ]
12 120 hour (CMJ)
Fonda 2013 11 30.5 (3) 11 31.4 (3.8) -0.90 [ -3.76, 1.96 ]
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Analysis 1.10. Comparison 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest),
Outcome 10 Power (cycle ergometer: % of baseline).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 1 Whole-body cryotherapy (WBC) versus control (no WBC or passive rest)
Outcome: 10 Power (cycle ergometer: % of baseline)
Study or subgroup WBC Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 48 hour
Costello 2012 9 89.7 (9.9) 9 99.2 (12.2) -9.50 [ -19.76, 0.76 ]
2 72 hour
Costello 2012 9 99.9 (10.1) 9 97.8 (8.6) 2.10 [ -6.57, 10.77 ]
3 96 hour
Costello 2012 9 102.9 (8.1) 9 100.5 (10.8) 2.40 [ -6.42, 11.22 ]
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Analysis 2.1. Comparison 2 Whole-body cryotherapy (WBC) versus far infrared therapy, Outcome 1 Pain
(muscle soreness at rest: VAS).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 2 Whole-body cryotherapy (WBC) versus far infrared therapy
Outcome: 1 Pain (muscle soreness at rest: VAS)
Study or subgroup WBC Far-infrared therapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 hour
Hausswirth 2011 9 31.7 (23.8) 9 58.3 (18.4) -26.60 [ -46.25, -6.95 ]
2 24 hour
Hausswirth 2011 9 33.3 (26.1) 9 49.1 (29.1) -15.80 [ -41.34, 9.74 ]
3 48 hour
Hausswirth 2011 9 39 (24) 9 45.2 (29.1) -6.20 [ -30.84, 18.44 ]
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Analysis 2.2. Comparison 2 Whole-body cryotherapy (WBC) versus far infrared therapy, Outcome 2
Tiredness (0 [no tiredness] to 100 [maximum tiredness]).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 2 Whole-body cryotherapy (WBC) versus far infrared therapy
Outcome: 2 Tiredness (0 [no tiredness] to 100 [maximum tiredness])
Study or subgroup WBC Far-infrared therapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 hour
Hausswirth 2011 9 44.6 (26.3) 9 67.8 (21.3) -23.20 [ -45.31, -1.09 ]
2 24 hour
Hausswirth 2011 9 35.9 (19.4) 9 65.8 (20) -29.90 [ -48.10, -11.70 ]
3 48 hour
Hausswirth 2011 9 46.6 (24) 9 61.8 (15.9) -15.20 [ -34.01, 3.61 ]
-20 -10 0 10 20
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Analysis 2.3. Comparison 2 Whole-body cryotherapy (WBC) versus far infrared therapy, Outcome 3 Well-
being (0 [worst well-being] to 100 [optimal well-being]).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 2 Whole-body cryotherapy (WBC) versus far infrared therapy
Outcome: 3 Well-being (0 [worst well-being] to 100 [optimal well-being])
Study or subgroup WBC Far-infrared therapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 hour
Hausswirth 2011 9 74.9 (26.7) 9 67.9 (28.2) 7.00 [ -18.37, 32.37 ]
2 24 hour
Hausswirth 2011 9 87.1 (27.6) 9 66.9 (27.6) 20.20 [ -5.30, 45.70 ]
3 48 hour
Hausswirth 2011 9 81.2 (20.4) 9 72.4 (19.2) 8.80 [ -9.50, 27.10 ]
-50 -25 0 25 50
Favours Far-infrared Favours WBC
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Analysis 2.4. Comparison 2 Whole-body cryotherapy (WBC) versus far infrared therapy, Outcome 4
Strength (% of baseline).
Review: Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults
Comparison: 2 Whole-body cryotherapy (WBC) versus far infrared therapy
Outcome: 4 Strength (% of baseline)
Study or subgroup WBC Far-infrared therapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 hour
Hausswirth 2011 9 92.4 (8.3) 9 90.5 (7.7) 1.90 [ -5.50, 9.30 ]
2 24 hour
Hausswirth 2011 9 98.2 (5.2) 9 100.4 (6.8) -2.20 [ -7.79, 3.39 ]
3 48 hour
Hausswirth 2011 9 97.9 (3.9) 9 102.4 (4.4) -4.50 [ -8.34, -0.66 ]
4 72 hour
Hausswirth 2011 9 104.8 (7.1) 9 106.1 (6.1) -1.30 [ -7.42, 4.82 ]
5 96 hour
Hausswirth 2011 9 105 (7.1) 9 105.5 (10.9) -0.50 [ -9.00, 8.00 ]
-10 -5 0 5 10
Favours Far-infrared Favours WBC
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL (Wiley Online Library)
#1 MeSH descriptor: [Cryotherapy] this term only (475)
#2 MeSH descriptor: [Hypothermia, Induced] this term only (753)
#3 cryotherapy:ti,ab,kw (Word variations have been searched) (1027)
#4 cryostimulation:ti,ab,kw (Word variations have been searched) (2)
#5 cooling:ti,ab,kw (Word variations have been searched) (1720)
#6 ((cold or cool*) near/3 (air or treat* or chamber*)):ti,ab,kw (Word variations have been searched) (726)
#7 “liquid nitrogen”:ti,ab,kw (Word variations have been searched) (142)
#8 low near/2 temp*:ti,ab,kw (Word variations have been searched) (427)
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 (4060)
#10 MeSH descriptor: [Exercise] explode all trees (14383)
#11 MeSH descriptor: [Sports] this term only (669)
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#12 MeSH descriptor: [Muscle, Skeletal] this term only (5028)
#13 MeSH descriptor: [Athletic Injuries] this term only (521)
#14 MeSH descriptor: [Soft Tissue Injuries] this term only (71)
#15 MeSH descriptor: [Creatine Kinase] explode all trees (1254)
#16 MeSH descriptor: [Physical Exertion] this term only (3338)
#17 MeSH descriptor: [Muscle Fatigue] this term only (596)
#18 MeSH descriptor: [Muscle Cramp] this term only (138)
#19 MeSH descriptor: [Spasm] this term only (181)
#20 MeSH descriptor: [Muscle Rigidity] this term only (59)
#21 MeSH descriptor: [Sprains and Strains] this term only (295)
#22 MeSH descriptor: [Muscle Weakness] this term only (272)
#23 sore* near/3 musc*:ti,ab,kw (Word variations have been searched) (472)
#24 DOMS:ti,ab,kw (Word variations have been searched) (135)
#25 (exercise induced and (muscle* near/2 (damage* or injur*))):ti,ab,kw (Word variations have been searched) (250)
#26 MeSH descriptor: [Lactic Acid] this term only (1730)
#27 lactate* or lactic:ti,ab,kw (Word variations have been searched) (7071)
#28# 10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
(28127)
#29 #9 and #28 Publication Year from 2013 to 2015 (388) [trials]
MEDLINE (Ovid Online)
1 Cryotherapy/ (4011)
2 Hypothermia, Induced/ (17249)
3 cryotherapy.tw. (5716)
4 cryostimulation.tw. (45)
5 cooling.tw. (28287)
6 ((cold or cool*) adj3 (air or treat* or chamber*)).tw. (5673)
7 “liquid nitrogen”.tw. (6876)
8 (low adj2 temp*).tw. (42977)
9 or/1-8 (101089)
10 Exercise/ (71646)
11 Sports/ (24259)
12 Muscle, Skeletal/ (110110)
13 Athletic Injuries/ (21484)
14 Soft Tissue Injuries/ (3943)
15 exp Creatine Kinase/ (24183)
16 Physical Exertion/ (53739)
17 Muscle Fatigue/ (6144)
18 Muscle Cramp/ or Spasm/ or Muscle Rigidity/ or “Sprains and Strains”/ or Muscle Weakness/ (19715)
19 (sore$ adj3 musc$).tw. (1339)
20 DOMS.tw. (452)
21 (exercise induced and (muscle$ adj2 (damage$ or injur$))).tw. (722)
22 Lactic Acid/ (33460)
23 (lactate$ or lactic).tw. (115241)
24 or/10-23 (416548)
25 9 and 24 (3169)
26 Randomized controlled trial.pt. (406278)
27 Controlled clinical trial.pt. (91297)
28 randomized.ab. (329655)
29 placebo.ab. (166774)
30 Clinical trials as topic/ (177484)
31 randomly.ab. (237727)
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32 trial.ti. (145097)
33 26 or 27 or 28 or 29 or 30 or 31 or 32 (987830)
34 exp Animals/ not Humans/ (4084521)
35 33 not 34 (911579)
36 25 and 35 (332)
EMBASE (Ovid Online)
1 Cryotherapy/ (13557)
2 Induced Hypothermia/ (11090)
3 cryotherapy.tw. (7578)
4 cryostimulation.tw. (67)
5 cooling.tw. (31796)
6 ((cold or cool*) adj3 (air or treat* or chamber*)).tw. (6950)
7 “liquid nitrogen”.tw. (8759)
8 (low adj2 temp*).tw. (39013)
9 or/1-8 (105759)
10 Exercise/ (202759)
11 exp Sport/ (113046)
12 Skeletal Muscle/ (88670)
13 Sport Injury/ (25404)
14 Sport Injury/ (25404)
15 Creatine Kinase/ (37855)
16 Muscle Fatigue/ or Muscle Spasm/ or Muscle Cramp/ or Muscle Weakness/ or Muscle Rigidity/ (66767)
17 (sore* adj3 musc*).tw. (1530)
18 DOMS.tw. (515)
19 (exercise induced and (muscle* adj2 (damage* or injur*))).tw. (777)
20 Lactic Acid/ (51949)
21 (lactate* or lactic).tw. (136672)
22 or/10-21 (613290)
23 9 and 22 (4416)
24 exp Randomized Controlled Trial/ or exp Single Blind Procedure/ or expDouble Blind Procedure/ or Crossover Procedure/ (431724)
25 (random* or RCT or placebo or allocat* or crossover* or ’cross over’ or trial or (doubl* adj1 blind*) or (singl* adj1 blind*)).ti,ab.
(1434026)
26 24 or 25 (1511947)
27 (exp Animal/ or animal.hw. or Nonhuman/) not (exp Human/ or Human Cell/ or (human or humans).ti.) (5673507)
28 26 not 27 (1331832)
29 23 and 28 (463)
CINAHL (Ebsco)
S1 (MH “Cryotherapy”) (1,636)
S2 (MH “Hypothermia, Induced”) (2,854)
S3 TX cryotherapy (2,028)
S4 TX cryostimulation (15)
S5 TX cooling (1,823)
S6 TX ((cold or cool*) n3 (air or treat* or chamber*)) (615)
S7 TX “liquid nitrogen” (147)
S8 TX low n2 temp* (507)
S9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 (6,985)
S10 (MH “Exercise”) (31,154)
S11 (MH “Recovery, Exercise”) (1,708)
S12 (MH “Muscle, Skeletal”) (16,524)
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S13 (MH “Athletic Injuries+”) (15,373)
S14 (MH “Creatine Kinase+”) (2,481)
S15 (MH “Muscle Fatigue”) (2,041)
S16 (MH “Muscle Cramp”) (458)
S17 (MH “Muscle Weakness”) (2,705)
S18 (MH “Sprains and Strains”) (1,851)
S19 sore* n3 musc* (658)
S20 DOMS (175)
S21 TX (exercise induced and (muscle* n2 (damage* or injur*))) (293)
S22 (MH “Lactic Acid”) (1,769)
S23 TX lactate* or lactic (9,377)
S24 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 (78,164)
S25 S9 AND S24 (505)
S26 (MH “Clinical Trials+”) (190,046)
S27 (MH “Evaluation Research+”) (21,423)
S28 (MH “Comparative Studies”) (81,240)
S29 (MH “Crossover Design”) (13,149)
S30 PT Clinical Trial (78,277)
S31 (MH “Random Assignment”) (39,485)
S32 S26 or S27 or S28 or S29 or S30 or S31 (298,918)
S33 TX ((clinical or controlled or comparative or placebo or prospective or randomi?ed) and (trial or study)) (547,042)
S34 TX (random* and (allocat* or allot* or assign* or basis* or divid* or order*)) (71,634)
S35 TX ((singl* or doubl* or trebl* or tripl*) and (blind* or mask*)) (798,149)
S36 TX ( crossover* or ’cross over’ ) or TX cross n1 over (16,303)
S37 TX ((allocat* or allot* or assign* or divid*) and (condition* or experiment* or intervention* or treatment* or therap* or control*
or group*)) (89,578)
S38 S33 or S34 or S35 or S36 or S37 (1,239,776)
S39 S32 or S38 (1,311,825)
S40 S25 AND S39 (286)
British Nursing Index (ProQuest)
((ti(cryotherapy OR cryostimulation OR cooling) OR ab(cryotherapy OR cryostimulation OR cooling)) OR ((cold OR cool*) NEAR/
3 (air OR treat* OR chamber*)) OR “liquid nitrogen” OR (low NEAR/2 tempo*)) AND (SU.EXACT.EXPLODE(“Physical Fitness”)
OR SU.EXACT.EXPLODE(“Sports Medicine”) OR (exercise OR sport* ORmuscle* OR “creatine kinase” OR cramp OR spasm OR
rigidity OR sprain OR strain OR domes OR “lactic acid”)) (5)
PEDro
1. Abstract and title: cryotherapy
Method: clinical trial (70)
2. Abstract and title: cold air
Method: clinical trial (17)
WHO International Clinical Trials Registry Platform
1. cryotherapy AND sore* OR cryotherapy AND pain OR cryotherapy AND recovery OR cryotherapy AND fatigue OR cryotherapy
AND damage* OR cryotherapy AND injur* (38)
2. cold AND muscle (25)
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Current Controlled Trials
(cryotherapy OR cryostimulation OR cold OR cool*) AND (soreness OR pain OR recovery OR fatigue OR damage OR injury) AND
muscle (32)
(cryotherapy OR cryostimulation OR cold OR cool*) AND (soreness OR pain OR recovery OR fatigue OR damage OR injury) AND
exercise (38)
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JTC, GMM, IBS, PRAB, and CMB developed the research idea, and wrote the original protocol.
Study selection was carried out by JTC and GMM.
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D E C L A R A T I O N S O F I N T E R E S T
Joseph Costello (Costello 2012a) and François Bieuzen (Hausswirth 2011; Pournot 2011) co-authored studies that are included in this
review. Decisions on inclusion of these studies, the risk of bias assessment and data extraction of these studies were undertaken by other
review authors (IBS, PRAB, CB and GMM), who had no involvement in the studies.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Since publication of the protocol (Costello 2013) the following changes were made:
1. We now state explicitly that cross-over trials are included.
2. We now state explicitly that trials that did not report any of our prespecified primary outcomes are excluded.
3. As the studies differed in the outcome measures used, the standard mean difference was calculated.
4. For objective outcome measures related to strength, we report percentage change from baseline, instead of our planned analysis
which was to use final scores in preference.
5. We have included study design (parallel versus cross-over) as a subgroup analysis.
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